Seth S. Martin

Seth S. Martin, MD, MHS                                             June 3rd, 2018

DEMOGRAPHIC AND PERSONAL INFORMATION

 

Current Appointments 

University

2015-present

 

Hospital

 Assistant Professor of Medicine and Cardiology, Johns Hopkins University School of Medicine
2015-present Attending Physician, Department of Medicine and Division of Cardiology, The Johns Hopkins Hospital
2016-present

 

Other

 Hopkins Bedside Medicine Faculty, Department of Medicine, The Johns Hopkins Hospital
2015-present Core Faculty, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease
2015-2018 Co-Director, Advanced Lipid Disorders Program, Ciccarone Center
2018-present Director, Advanced Lipid Disorders Program, Ciccarone Center
2016-present Firm Faculty Clinical Coach and Educator, Janeway Firm, Osler Medical Residency
2016-present Associate Faculty, Welch Center for Prevention, Epidemiology, and Clinical Research
2017-present

 

Personal Data

 Affiliate Faculty, Malone Center for Engineering in Healthcare
              Cardiology
              Medicine
              Carnegie 591
              Johns Hopkins Hospital
              600 N. Wolfe St.
              Baltimore, MD 21287

Education & Training

Undergraduate

2000-2004        B.S., Biology, Washington & Lee University, Lexington, VA

Doctoral/Graduate

2004-2008        M.D., Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

2013-2015        M.H.S., Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

 

Postdoctoral

2008-2009        Intern, Duke University Medical Center, Durham, NC

2009-2011        Resident, Duke University Medical Center, Durham, NC

2011-2015        Cardiology Fellow, Johns Hopkins University School of Medicine, Baltimore, MD

 

Professional Experience

2015-present Assistant Professor of Medicine and Cardiology, Johns Hopkins University School of Medicine
2015-present Attending Physician, Department of Medicine and Division of Cardiology, The Johns Hopkins Hospital
2016-present Hopkins Bedside Medicine Faculty, Department of Medicine, The Johns Hopkins Hospital
2015-present Core Faculty, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease
2015-2018 Co-Director, Advanced Lipid Disorders Program, Ciccarone Center 
2018-present Director, Advanced Lipid Disorders Program, Ciccarone Center
2016-present Firm Faculty Clinical Coach and Educator, Janeway Firm, Osler Medical Residency

2016-present     Associate Faculty, Welch Center for Prevention, Epidemiology, and Clinical Research 2017-present             Affiliate Faculty, Malone Center for Engineering in Healthcare

PUBLICATIONS

   Google Scholar Public Profile: http://scholar.google.com/citations?user=mGx0e8EAAAAJ&hl=en    Research Gate Public Profile: https://www.researchgate.net/profile/Seth_Martin3

Original Research [OR]

  1. Martin JL, Pensyl C, Mayhew K, Martin SS, Patel N. Complex PCI with rotational atherectomy and stenting utilizing subcutaneous enoxaparin and point-of-care testing. J Invasive Cardiol. 2003;5:1-4.
  2. Martin SS. From poverty to obesity: exploration of the food choice constraint model and the impact of an energydense food tax. Am Econ. 2005;49:78-86.
  3. Martin JL, Jia G, Martin SS, Shapiro TA, Herrmann HC, Dibattiste PM, Topol EJ, Moliterno DJ. The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. Catheter Cardiovasc Interv. 2006;67:563-70.
  4. Martin JL, Fry ET, Martin T, Atherley TH, Martin SS, Slepian MJ. The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study). J Thromb Thrombolysis. 2009;28:224-8.
  5. Martin SS, Qasim AN, Mehta NN, Wolfe M, Terembula K, Schwartz S, Iqbal N, Schutta M, Bagheri R, Reilly MP.

Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes. 2009;58:1887-92.

  1. Zhu TG, Patel C, Martin SS, Quan X, Wu Y, Burke JF, Chernick M, Kowey PR, Yan GX. Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. Eur Heart J. 2009;30:372-80.
  2. Qasim AN, Martin SS, Mehta NN, Wolfe ML, Park J, Schwartz S, Schutta M, Iqbal N, Reilly MP. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol. 2011;150:17-21.
  3. Mehta NN, Krishnamoorthy P, Martin SS, St Clair C, Schwartz S, Iqbal N, Braunstein S, Schutta M, Rader DJ, Reilly MP. Usefulness of insulin resistance estimation and the metabolic syndrome in predicting coronary atherosclerosis in type 2 diabetes mellitus. Am J Cardiol. 2011;107:406-11.
  4. Martin SS, Qasim AN, Wolfe M, St Clair C, Schwartz S, Iqbal N, Schutta M, Bagheri R, Mehta NN, Rader DJ, Reilly MP. Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance. Am J Cardiol. 2011;107:393-8.
  5. Martin SS, Qasim AN, Rader DJ, Reilly MP. C-reactive protein modifies the association of plasma leptin with coronary calcium in asymptomatic overweight individuals. 2012;20:856-61.
  6. Martin SS, Gosch K, Kulkarni K, Spertus JA, Mathews R, Newby LK, Alexander KP, Wang TY. Patient and provider factors in lipid goal attainment after acute myocardial infarction: insights from the Translational Research Investigating Underlying disparities in Acute Myocardial Infarction Patients’ Health Status (TRIUMPH) study. Am Heart J. 2013;165:26-33; corresponding author.
  7. Martin SS, Ou FS, Newby LK, Sutton V, Adams P, Felker GM, Wang TY. Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials. J Am Coll Cardiol. 2013;61:762-9; corresponding author.
  8. DeFilippis AP, Blaha MJ, Martin SS, Reed R, Jones SR, Budoff M, Blumenthal RS, Nasir K. Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis. 2013;227:429-36.
  9. Makadia SS, Blaha M, Keenan T, Ndumele C, Jones S, Defilippis A, Martin SS, Kohli P, Conceicao R, Carvalho J, Nasir K, Blumenthal R, Santos R. Relation of hepatic steatosis to atherogenic dyslipidemia. Am J Cardiol. 2013;112:1599-604.
  10. Martin SS, Blaha MJ, Elshazly M, Brinton EA, Toth PT, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD,

Kwiterovich PO, DeFilippis AP, Blumenthal RS, Jones SR. Accuracy of low-density lipoprotein cholesterol estimation by the Friedewald equation and treatment implications. J Am Coll Cardiol. 2013;62:732-9; corresponding author.

  1. Ahmed HM, Elshazly MB, Martin SS, Blaha MJ, Kulkarni KR, Jones SR. Ratio of dense to buoyant LDL subclass is associated with LDL density phenotype (VLDL-5). Open Chem Biomed Meth J. 2013;6:1-5.
  2. Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, Al–Hijji MA, Kulkarni KR, Kwiterovich PO, Blumenthal RS, Jones SR. Non-HDL cholesterol, guideline targets, and population percentiles for secondary prevention in a clinical sample of 1.3 million adults: The Very Large Database of Lipids (VLDL-2 Study). J Am Coll Cardiol. 2013;62:1960-5.
  3. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and metaanalysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88:1213-21; corresponding author.
  4. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. 2013;310:2061-8; corresponding author.
  5. Martin SS, Blaha MJ, Blankstein R, Agatston AS, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the Multi-Ethnic Study of Atherosclerosis. 2014;129:77-86.
  6. Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AA, Blumenthal RS, Meneghelo RS, Conceiçao RD, Santos RD, Nasir K. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res. 2014;45:52-7.
  7. Swiger KJ, Martin SS, Blaha MJ, Toth PP, Nasir K, Michos ED, Gerstenblith G, Blumenthal RS, Jones SR.

Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: The Very Large Database of Lipids (VLDL-10B). J Am Heart Assoc. 2014;3:e000851.

  1. Pokharel Y, Macedo FY, Nambi V, Martin SS, Nasir K, Wong ND, Boone J, Roberts AJ, Ballantyne CM, Virani SS. Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014;37:402-7.
  2. Pokharel Y, Nambi V, Martin SS, Hoogeveen RC, Nasir K, Khera A, Wong ND, Jones PH, Boone J, Roberts AJ, Ballantyne CM, Virani SS. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in retired national football league players. 2014;236:251-6.
  3. Basra SS, Pokharel Y, Hira RS, Bandeali SJ, Nambi V, Deswal A, Nasir K, Martin SS, Vogel RA, Roberts AJ, Ballantyne CM, Virani SS. Relation between playing position and coronary artery calcium scores in retired national football league players. Am J Cardiol. 2014;114:1836-40.
  4. Blaha MJ, Dardari ZA, Blumenthal RS, Martin SS, Nasir K, Al-Mallah MH. The new “intermediate risk” group: A comparative analysis of the new 2013 ACC/AHA risk assessment guidelines versus prior guidelines in men. 2014;237:1-4.
  5. Swiger KJ, Manalac RJ, Blaha MJ, Blumenthal RS, Martin SS. Statins, mood, sleep, and physical function: a systematic review. Eur J Clin Pharmacol. 2014;70:1413-22; corresponding author.
  6. Malik R, Aneni EC, Roberson L, Ogunmoroti O, Ali SS, Shaharyar S, Younus A, Jamal O, Aziz MA, Martin SS, Blaha MJ, Feldman T, Agatston AS, Veledar E, Nasir K. Measuring coronary artery calcification: Is serum vitamin D relevant? 2014;237:734-8.
  7. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR; on behalf of the Lipoprotein Investigators Collaborative (LIC). HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J. 2015;36:22-30; corresponding author.
  8. Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, Veledar E, Conçeicao RD, Carvalho JA, Santos RD, Nasir K. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33:1207-14.
  9. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, Nasir K, Criqui MH, McClelland RL, Hughes-Austin JM, Allison MA. Leptin and incident cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). 2015;239:67-72; corresponding author.
  10. Oni ET, Kalathiya R, Aneni EC, Martin SS, Blaha MJ, Feldman T, Agatston AS, Blumenthal RS, Conceiçao RD, Carvalho JA, Santos RD, Nasir K. Relation of physical activity to prevalence of nonalcoholic fatty liver disease independent of cardiometabolic risk. Am J Cardiol. 2015;115:34-9.
  11. Roberts ET, Horne A, Martin SS, Blaha MJ, Blankstein R, Budoff MJ, Sibley C, Polak JF, Frick KD, Blumenthal RS, Nasir K. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: The Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2015;10:e0116377.
  12. Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, Kostner K, Blaha MJ, Martin SS, Rysz J, Glasser S,

Ray KK, Watts GF, Mikhailidis DP, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015;242:87-96.

  1. Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, Nasir K, Virani SS, Banach M, Blumenthal RS, Martin SS, Jones SR. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. 2015;242:243-50.
  2. Quispe R, Al-Hijji M, Swiger KJ, Martin SS, Elshazly MB, Blaha MJ, Joshi PH, Blumenthal RS, Sniderman AD, Toth PP, Jones SR. Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The Very Large Database of Lipids-9. J Clin Lipidol. 2015;9:511-8.
  3. Swiger KJ, Martin SS, Tang F, Blaha MJ, Blumenthal RS, Alexander KP, Arnold SV, Spertus JA. Cognitive and physical function by statin exposure in elderly individuals following acute myocardial infarction. Clin Cardiol. 2015;38:455-61.
  4. Elshazly MB, Quispe R, Michos ED, Sniderman AD, Toth PP, Banach M, Kulkarni KR, Coresh J, Blumenthal RS, Jones SR, Martin SS. Patient-level discordance in population percentiles of the TC/HDL-C ratio compared with LDL-C and Non-HDL-C: The Very Large Database of Lipids Study (VLDL-2B). Circulation. 2015;132:667-76.
  5. Miller PE, Martin SS, Toth PP, Santos RD, Blaha MJ, Nasir K, Virani SS, Post WS, Blumenthal RS, Jones SR. Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study17 (VLDL-17). J Clin Lipidol. 2015;9:676-83.
  6. Aneni EC, Oni ET, Osondu CU, Martin SS, Blaha MJ, Veledar E, Agatston AS, Feldman T, Carvalho JA, Conceição RD, Santos RD, Nasir K. Obesity modifies the effect of fitness on heart rate indices during exercise stress testing in asymptomatic individuals. Cardiology. 2015;132:242-8.
  7. Martin SS, Feldman DI, Blumenthal RS, Jones SR, Post WS, McKibben RA, Michos ED, Ndumele CE, Ratchford EV, Coresh J, Blaha MJ. mActive: A randomized clinical trial of an automated mHealth intervention for physical activity promotion. J Am Heart Assoc. 2015 Nov 9;4(11) ; corresponding author.
  8. Martin SS, Faridi KF, Joshi PH, Blaha MJ, Kulkarni KR, Khokhar AA, Maddox TM, Havranek EP, Toth PP, Tang F, Spertus JA, Jones SR. Remnant lipoprotein cholesterol and mortality after acute myocardial infarction: Further evidence for a hypercholesterolemia paradox from the TRIUMPH Registry. Clin Cardiol. 2015;38:660-7; corresponding author.
  9. Besseling J, Huijgen R, Martin SS, Hutten BA, Kastelein JJ, Hovingh GK. Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia. Atherosclerosis. 2015;246:1-6.
  10. Joshi PH, Toth PP, Lirette ST, Griswold ME, Massaro JM, Martin SS, Blaha MJ, Kulkarni KR, Khokhar AA, Correa A, D’Agostino RB Sr., Jones SR, on behalf of the Lipoprotein Investigators Collaborative (LIC) Study Group. Association of high-density lipoprotein subclasses and incident coronary heart disease: the Jackson Heart and Framingham Offspring cohort studies. Eur J Prev Cardiol. 2016;23:41-9.
  11. Miller PE, Martin SS, Joshi PH, Jones SR, Massaro JM, D’Agostino RB, Sponseller CA, Toth PP. Pitavastatin 4 mg provides significantly greater reduction in remnant lipoprotein cholesterol compared with pravastatin 40 mg: Results from the short-term Phase IV PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia. Clin Ther. 2016;38:603-9.
  12. Plante TB, Urrea B, MacFarlane ZT, Blumenthal RS, Miller ER 3rd, Appel LJ, Martin SS. Validation of the Instant Blood Pressure smartphone app. JAMA Intern Med. 2016;176:700-2.
  13. Lupton JR, Faridi KF, Martin SS, Sharma S, Kulkarni K, Jones SR, Michos ED. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study. J Clin Lipidol. 2016;10:72-81.
  14. Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, Blaha MJ, Andrica F, Martin SS, Borza C, Lip GY, Ray KK, Rysz J, Hazen SL, Banach M. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016;6:19188.
  15. Toth PP, Hamon SC, Jones SR, Martin SS, Joshi PH, Kulkarni KR, Banerjee P, Hanotin C, Roth EM, McKenney JM. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016;15:28.
  16. Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacol Res. 2016;103:236-52.
  17. Elshazly MB, Nicholls SJ, Nissen SE, St John J, Martin SS, Jones SR, Quispe R, Stegman B, Kapadia SR, Tuzcu EM, Puri R. Implications of total to high-density lipoprotein cholesterol ratio discordance with alternative lipid parameters for coronary atheroma progression and cardiovascular events. Am J Cardiol. 2016;118:647-55.
  18. Banach M, Dinca M, Ursoniu S, Serban MC, Howard G, Mikhailidis DP, Nicholls S, Lip GY, Glasser S, Martin SS, Muntner P, Rysz J, Toth PP, Sahebkar A; Lipid Blood Pressure Meta-analysis Collaboration Group. A PRISMAcompliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacol Res. 2016;111:343-356.
  19. Banach M, Serban MC, Sahebkar A, García-García HM, Mikhailidis DP, Martin SS, Brie D, Rysz J, Toth PP, Jones SR, Hasan RK, Mosteoru S, Al Rifai M, Pencina MJ, Serruys PW. Comparison of clinical outcomes between bioresorbable vascular stents versus conventional drug-eluting and metallic stents: a systematic review and metaanalysis. EuroIntervention. 2016;12(2):e175-89.
  20. Joshi PH, Khokhar AA, Massaro JM, Lirette ST, Griswold ME, Martin SS, Blaha MJ, Kulkarni KR, Correa A, D’Agostino RB Sr, Jones SR, Toth PP; Lipoprotein Investigators Collaborative (LIC) Study Group. Remnant lipoprotein cholesterol and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. J Am Heart Assoc. 2016 Apr 29;5(5).
  21. Lupton JR, Quispe R, Kulkarni K, Martin SS, Jones SR. Serum homocysteine is not independently associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-21) study. Atherosclerosis. 2016;249:59-64.
  22. Dinca M, Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Martin SS, Blaha MJ, Blüher M, Gurban C, Penson P,

Michos ED, Hernandez AV, Jones SR, Banach M; for Lipid Blood Pressure Meta-analysis Collaboration LBPMC Group. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and metaanalysis of randomized controlled trials. Pharmacol Res. 2016;107:360-71.

  1. Cheng HG, Patel BS, Martin SS, Blaha M, Doneen A, Bale B, Jones SR. Effect of comprehensive cardiovascular disease risk management on longitudinal changes in carotid artery intima-media thickness in a community-based prevention clinic. Arch Med Sci. 2016;12(4):728-35.
  2. Gandapur Y, Kianoush S, Kelli HM, Misra S, Urrea B, Blaha MJ, Graham G, Marvel FA, Martin SS. The role of mHealth for improving medication adherence in patients with cardiovascular disease: A systematic review. Eur Heart J Qual Care Clin Outcomes. 2016;2(4):237-244.
  3. Farag YM, Guallar E, Zhao D, Kalyani RR, Blaha MJ, Feldman DI, Martin SS, Lutsey PL, Billups KL, Michos ED. Vitamin D deficiency is independently associated with greater prevalence of erectile dysfunction: The National Health and Nutrition Examination Survey (NHANES) 2001-2004. Atherosclerosis. 2016;252:61-67.
  4. Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S, Blaha

MJ, Martin SS, Rysz J, Toth PP, Lip GY, Pencina MJ, Ray KK, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208.

  1. Kotani K, Sahebkar A, Serban MC, Ursoniu S, Mikhailidis DP, Mariscalco G, Jones SR, Martin S, Blaha MJ, Toth PP, Rizzo M, Kostner K, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.

Lipoprotein(a) levels in patients with abdominal aortic aneurysm: A systematic review and meta-analysis. Angiology. 2017;68(2):99-108.

  1. Miller PE, Zhao D, Frazier-Wood AC, Michos ED, Averill M, Sandfort V, Burke GL, Polak JF, Lima JA, Post WS, Blumenthal RS, Guallar E, Martin SS. Associations between coffee, tea, and caffeine intake with coronary artery calcification and cardiovascular events. Am J Med. 2017;130(2):188-197.
  2. McEvoy JW, Martin SS, Dardari ZA, Miedema MD, Sandfort V, Yeboah J, Budoff MJ, Goff DC, Psaty BM, Post WS, Nasir K, Blumenthal RS, Blaha MJ. Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. Circulation. 2017;135(2):153-165.
  3. Joshi PH, Miller PE, Martin SS, Jones SR, Massaro JM, D’Agostino RB Sr, Kulkarni KR, Sponseller C, Toth PP.

Greater remnant lipoprotein cholesterol reduction with pitavastatin compared to pravastatin in HIV-infected patients: The INTREPID trial. AIDS. 2017;31(7):965-971.

  1. Chin K, Zhao D, Tibuakuu M, Martin SS, Ndumele CE, Florido R, Windham BG, Guallar E, Lutsey PL, Michos ED. Physical activity, vitamin D, and incident atherosclerotic cardiovascular disease in Whites and Blacks: The ARIC Study. J Clin Endocrinol Metab. 2017;102(4):1227-1236.
  2. Faridi KF, Lupton JR, Martin SS, Banach M, Quispe R, Kulkarni K, Jones SR, Michos ED. Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk. Arch Med Sci. 2017;13(4):732-737.
  3. Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition. 2017;38:8593.
  4. Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW, Blumenthal RS, Coresh J, Greenland P, Kottgen

A, Selvin E. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Endocrinol Metab. 2017;102:3306-3315; corresponding author.

  1. Whelton SP, Meeusen J, Donato LJ, Jaffe AS, Saenger A, Sokoll LJ, Blumenthal RS, Jones SR, Martin SS. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. J Clin Lipidol. 2017;11(4):1065-1072.
  2. Sathiyakumar V, Park J, Golozar A, Lazo M, Quispe R, Guallar E, Blumenthal RS, Jones SR, Martin SS. Fasting vs non-fasting and low-density lipoprotein-cholesterol accuracy. Circulation. 2017;137:10-19; corresponding author.
  3. Amrock SM, Duell PB, Knickelbine T, Martin SS, O’Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ,

Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR,

Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. Atherosclerosis. 2017;267:19-26.

  1. Pokharel Y, Tang Y, Bhardwaj B, Patel KK, Qintar M, O’Keefe JH Jr, Kulkarni KR, Jones PH, Martin SS, Virani SS, Spertus JA. Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. J Clin Lipidol. 2017;11(6):1458-1470.e4.
  2. Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Effect of evolocumab on lipoprotein particles. Am J Cardiol. 2018;121(3):308-314.
  3. Aronis KN, Zhao D, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, Virani SS, Michos ED. Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017;6(12). pii: e007372.
  4. Sathiyakumar V, Park J, Quispe R, Elshazly MB, Michos ED, Banach M, Toth PP, Whelton SP, Blumenthal RS, Jones SR, Martin SS. Impact of novel LDL-C assessment on the utility of secondary non-HDL-C and apoB targets in selected worldwide dyslipidemia guidelines. Circulation. 2018 Mar 5. pii: CIRCULATIONAHA.117.032463. doi:

10.1161/CIRCULATIONAHA.117.032463. [Epub ahead of print]; corresponding author.

  1. Fujita S, Pitaktong I, Steller GV, Dadfar V, Huang Q, Banerjee S, Guo R, Nguyen HT, Allen RH, Martin SS. Pilot study of a smartphone application designed to socially motivate cardiovascular disease patients to improve medication adherence. Mhealth. 2018 Jan 3;4:1. doi: 10.21037/mhealth.2017.11.01; corresponding author.
  2. Silverman-Lloyd LG, Kianoush S, Blaha MJ, Sabina AB, Graham GN, Martin SS. mActive-Smoke: A prospective observational study using mobile health tools to assess the association of physical activity with smoking urges. JMIR Mhealth Uhealth. 2018 May 11;6(5):e121. doi: 10.2196/mhealth.9292; corresponding author.
  3. Ong KL, Morris MJ, McClelland RL, Hughes TM, Maniam J, Fitzpatrick AL, Martin SS, Luchsinger JA, Rapp SR, Hayden KM, Sandfort V, Allison MA, Rye KA. Relationship of lipids and lipid-lowering medications with cognitive function: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2018;187(4):767-776.
  4. Al Rifai M, Martin SS, McEvoy JW, Nasir K, Blankstein R, Yeboah J, Miedema M, Shea SJ, Polak JF, Ouyang P, Blumenthal RS, Bittencourt M, Bensenor I, Santos RD, Duncan BB, Santos IS, Lotufo PA, Blaha MJ. The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol <70 mg/dL: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Atherosclerosis. 2018;274:61-66.

Review Articles [RA]

  1. Martin SS. Antiatherogenic effects of red wine polyphenols. W&L J Science. 2005;6:12-7.
  2. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesityrelated cardiovascular disease. J Am Coll Cardiol. 2008;52:1201-10.
  3. Joshi PH, Chaudhari S, Blaha MJ, Jones SR, Martin SS, Post WS, Cannon CP, Fonarow GC, Wong ND, Amsterdam E, Hirshfeld JW, Blumenthal RS. A point-by-point response to recent arguments against the use of statins in primary prevention: endorsed by the American Society for Preventive Cardiology. Clin Cardiol. 2012;35:404-9.
  4. Hsu S, Ton VK, Dominique Ashen M, Martin SS, Gluckman TJ, Kohli P, Sisson SD, Blumenthal RS, Blaha MJ. A clinician’s guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clin Cardiol. 2013;36:383-93.
  5. Chrispin J, Martin SS, Hasan RK, Joshi PH, Minder CM, McEvoy JW, Kohli P, Johnson AE, Wang L, Blaha MJ, Blumenthal RS. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease. Clin Cardiol. 2013;36:516-23.
  6. Ton VK, Martin SS, Blumenthal RS, Blaha MJ. Comparing the new European cardiovascular disease prevention guideline with prior American Heart Association guidelines: an editorial review. Clin Cardiol. 2013;36:E1-6.
  7. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ. High-sensitivity Creactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397-408.
  8. Czarny MJ, Martin SS, Kohli P, Metkus T, Blumenthal RS. Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters? Circ Cardiovasc Qual Outcomes. 2014;7:481-5.
  9. Kohli P, Whelton SP, Hsu S, Yancy CW, Stone NJ, Chrispin J, Gilotra NA, Houston B, Ashen MD, Martin SS, Joshi PH, McEvoy JW, Gluckman TJ, Michos ED, Blaha MJ, Blumenthal RS. Clinician’s guide to the updated ABCs of cardiovascular disease prevention. J Am Heart Assoc. 2014;3:e001098.
  10. Patel J, Superko HR, Martin SS, Blumenthal RS, Christopher-Stine L. Genetic and immunologic susceptibility to statin-related myopathy. 2015;240:260-71.
  11. Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, Blaha MJ, Blumenthal RS, Calkins H. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol. 2015;66:2899-906.
  12. Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS. Cholesterol, statins, and dementia: What the cardiologist should know. Clin Cardiol. 2015;38:243-50; corresponding author.
  13. Driver SL, Martin SS, Gluckman TJ, Clary JM, Blumenthal RS, Stone NJ. Fasting or nonfasting lipid measurements: It depends on the question. J Am Coll Cardiol. 2016;67(10):1227-34.
  14. Lobelo F, Kelli HM, Tejedor SC, Pratt M, McConnell MV, Martin SS, Welk GJ. The wild wild west: A framework to integrate mHealth software applications and wearables to support physical activity assessment, counseling and interventions for cardiovascular disease risk reduction. Prog Cardiovasc Dis. 2016;58:584-94.
  15. McEvoy JW, Martin SS, Blaha MJ, Polonsky TS, Nasir K, Kaul S, Greenland P, Blumenthal RS. The case for and against a coronary artery calcium trial: Means, motive, and opportunity. JACC Cardiovasc Imaging. 2016;9(8):994-1002.
  16. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D,

Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-2561.

  1. Streed CG Jr, Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M. Cardiovascular disease among transgender adults receiving hormone therapy: A narrative review. Ann Intern Med. 2017;167(4):256-267.
  2. Ratchford EV, Martin SS. Statins. Vasc Med. 2017;22(5):442-445.
  3. Rahman F, Martin SS, Whelton SP, Mody FV, Vaishnav J, McEvoy JW. Inflammation and cardiovascular disease Risk: A case study of HIV and inflammatory joint disease. Am J Med. 2017;131(4):442.e1-442.e8.
  4. Rahman F, Blumenthal RS, Jones SR, Martin SS, Gluckman TJ, Whelton SP. Fasting or non-fasting lipids for atherosclerotic cardiovascular disease risk assessment and treatment? Curr Atheroscler Rep. 2018 Feb 17;20(3):14. doi:

10.1007/s11883-018-0713-2.

  1. Wang J, Ashvetiya T, Quaye E, Parakh K, Martin SS. Online health searches and their perceived effects on patients and patient-clinician relationships: A systematic review. Am J Med. 2018 May 3. pii: S0002-9343(18)30396-6. doi:

10.1016/j.amjmed.2018.04.019. [Epub ahead of print]; corresponding author.

  1. Feldman DI, Robison WT, Pacor JM, Caddell LC, Feldman EB, Deitz RL, Feldman T, Martin SS, Nasir K, Blaha MJ. Harnessing mHealth technologies to increase physical activity and prevent cardiovascular disease. Clin Cardiol. 2018 Apr 19. doi: 10.1002/clc.22968. [Epub ahead of print].

Invited Expert Opinion Articles [EO]

  1. Subedi BH, Tota-Maharaj R, Silverman MG, Minder CM, Martin SS, Ashen MD, Blumenthal RS, Blaha MJ. The role of statins in diabetes mellitus. Diabetes Spectrum. 2013;26:156-64.
  2. Cruz DE, Ahmed HM, Jones SR, Elshazly MB, Martin SS. Discordance in lipid measurements: Can we capitalize to better personalize cardiovascular risk assessment and treatment? Curr Cardiovasc Risk Rep. 2014;8:1-8; corresponding author.
  3. Subedi BH, Joshi PH, Jones SR, Martin SS, Blaha MJ, Michos ED. Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. Vasc Health Risk Manag. 2014;10:205-16.
  4. Martin SS, Jones SR, Toth PP. High-density lipoprotein subfractions: current views and clinical practice applications. Trends Endocrinol Metab. 2014;25:329-36.
  5. Ankam J, Feldman DI, Blaha MJ, Martin SS. Improving lipid control following myocardial infarction. Curr Opin Cardiol. 2014;29:454-66; corresponding author.
  6. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014;349:g3743.
  7. Shah NP, Swiger KJ, Martin SS. Impact on cognitive function-are all statins the same? Curr Atheroscler Rep. 2015;17:466; corresponding author.
  8. Feldman DI, Blaha MJ, Santos RD, Jones SR, Blumenthal RS, Toth PP, Sperling LS, Martin SS. Recommendations for the management of patients with familial hypercholesterolemia. Curr Atheroscler Rep. 2015;17:473; corresponding author.
  9. Florido R, Elander A, Blumenthal RS, Martin SS. Statins and incident diabetes: Can risk outweigh benefit? Curr Cardiovasc Risk Rep. 2015;9;1-7; corresponding author.
  10. Martin SS, Shapiro EP, Mukherjee M. Atrial septal defects – clinical manifestations, echo assessment, and intervention. Clin Med Insights Cardiol. 2015;8(Suppl 1):93-8.
  11. Urrea B, Misra S, Plante TB, Kelli HM, Misra S, Blaha MJ, Martin SS. Mobile health initiatives to improve outcomes in primary prevention of cardiovascular disease. Curr Treat Options Cardiovasc Med. 2015;17:59; corresponding author.
  12. Cainzos-Achirica M, Eissler K, Blaha MJ, Blumenthal RS, Martin SS. Tools for cardiovascular risk assessment in clinical practice. Curr Cardiovasc Risk Rep. 2015;9:1-12; corresponding author.
  13. Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: Exploring the FDA directive and a proposal for n-of-1 trials. Drug Saf. 2015;38:519-26; corresponding author.
  14. Hendrani AD, Adesiyun T, Quispe R, Jones SR, Stone NJ, Blumenthal RS, Martin SS. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World J Cardiol. 2016;8:201-10; corresponding author.
  15. Miller PE, Martin SS. Approach to statin use in 2016: An update. Curr Atheroscler Rep. 2016;18(5):20; corresponding author.
  16. Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. Future Cardiol. 2016;12(2):149-57; corresponding author.
  17. Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A, Joshi PH, Swiger KJ, Byrne K, Quispe R, Jones SR, Blumenthal RS, Martin SS. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiol. 2016;12(2):139-48; corresponding author.
  18. Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2016;23:150-6.
  19. Same RV, Feldman DI, Shah N, Martin SS, Al Rifai M, Blaha MJ, Graham G, Ahmed HM. Relationship between sedentary behavior and cardiovascular risk. Curr Cardiol Rep. 2016;18:6.
  20. Navar AM, Stone NJ, Martin SS. What to say and how to say it: effective communication for cardiovascular disease prevention. Curr Opin Cardiol. 2016;31(5):537-44; corresponding author.
  21. Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother. 2016;17(11):1497-507.
  22. Kambhampati S, Ashvetiya T, Stone NJ, Blumenthal RS, Martin SS. Shared decision-making and patient empowerment in preventive cardiology. Curr Cardiol Rep. 2016;18(5):49; corresponding author.
  23. Dahagam C, Hahn VS, Goud A, D’Souza J, Abdelqader A, Blumenthal RS, Martin SS. Role of statins in glucose homeostasis and insulin resistance. Curr Cardiovasc Risk Rep. 2016;10:40; corresponding author.
  24. Sathiyakumar V, Blumenthal RS, Nasir K, Martin SS. Addressing knowledge gaps in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A review of recent coronary artery calcium literature. Curr Atheroscler Rep. 2017;19(2):7; corresponding author.
  25. Khan N, Marvel FA, Wang J, Martin SS. Digital health technologies to promote lifestyle change and adherence. Curr Treat Options Cardiovasc Med. 2017;19(8):60; corresponding author.
  26. Marvel FA, Wang J, Martin SS. Digital health innovation: A toolkit to navigate from concept to clinical testing. JMIR Cardio. 2018;2(1):e2; DOI: 10.2196/cardio.7586.

Guideline Consensus Articles & Critiques [GL]

  1. Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos

ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumenthal RS. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol. 2012;110:307-13; corresponding author.

  1. Martin SS, Abd TT, Jones SR, Michos ED, Blumenthal RS, Blaha MJ. 2013 ACC/AHA cholesterol treatment Guideline: what was done well and what could be done better. J Am Coll Cardiol. 2014;63:2674-8; corresponding author.
  2. Amin NP, Martin SS, Blaha MJ, Nasir K, Blumenthal RS, Michos ED. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol. 2014;63(25PA):2789-2794.
  3. Martin SS, Sperling LS, Blaha MJ, Wilson PW, Gluckman TJ, Blumenthal RS, Stone NJ. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: Importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65:1361-8; corresponding author.
  4. Cainzos-Achirica M, Desai CS, Wang L, Blaha MJ, Lopez-Jimenez F, Kopecky SL, Blumenthal RS, Martin SS.

Pathways forward in cardiovascular disease prevention one and a half years after publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines. Mayo Clin Proc. 2015;90:1262-71; corresponding author.

  1. Bennet CS, Dahagam CR, Virani SS, Martin SS, Blumenthal RS, Michos ED, McEvoy JW. Lipid management

guidelines from the Departments of Veteran Affairs and Defense: A critique. Am J Med. 2016;129(9):906-12.

Expert Roundtable Discussion Reports [RD]

  1. Brown WV, Handelsman Y, Martin SS, Morris PB. JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). J Clin Lipidol. 2017;11(4):846-854.
  2. Brown WV, Handelsman Y, Martin SS, Morris PB. JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1). J Clin Lipidol. 2017;11(3):587-595.

Methods Papers [MT]

  1. Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR. Very Large Database of Lipids:

rationale and design. Clin Cardiol. 2013;36:641-8; corresponding author.

 

Editorials [ED]

  1. Nasir K, Martin SS, Virani S. Discordance: Can we capitalize on it to better personalize atherosclerosis treatment? 2013;229:504-6.
  2. Blumenthal RS, Ndumele CE, Martin SS. ASK NOT What CRP Can Do for You. J Am Coll Cardiol. 2013;62:730-1.
  3. Al-Hijji M, Martin SS, Joshi PH, Jones SR. Effect of equivalent on-treatment apolipoprotein levels on outcomes (from the AIM-HIGH and HPS2-THRIVE). Am J Cardiol. 2013;112:1697-700.
  4. Blaha MJ, Martin SS. How do statins work? Changing paradigms with implications for statin allocation. J Am Coll Cardiol. 2013;62:2392-4.
  5. Martin SS, Michos ED. Are we moving towards concordance on the principle that lipid discordance matters? 2014;129:539-41.
  6. Martin SS, Blumenthal RS. Concepts and controversies: The 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines. Ann Intern Med. 2014;160:356-8.
  7. Martin SS, Blaha MJ. Genetically low triglycerides and mortality: further support for “the earlier the better”? Clin Chem. 2014;60:705-7.
  8. Martin SS, Joshi PH, Blaha MJ. High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle. 2014;237:838-9.
  9. Martin SS, Michos ED. Mapping hyperlipidemia in young adulthood to coronary risk: importance of cumulative exposure and how to stay young. 2015;131:445-7.
  10. Martin SS. My approach to patients intolerant to statins. Trends Cardiovasc Med. 2015;25:265-6.
  11. Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: A new era in lipid-lowering treatment? Ann Intern Med. 2015;163:64-5.
  12. Joshi PH, Martin SS, Blumenthal RS. The remnants of residual risk. J Am Coll Cardiol. 2015;65:2276-8.
  13. Michos ED, Martin SS, Blumenthal RS. Bringing back targets to “IMPROVE” atherosclerotic cardiovascular disease outcomes: The duel for dual goals, are two targets better than one? Circulation. 2015;132:1218-20.
  14. Martin SS, Hasan RK. Drug-eluting cardiac stents: Does bioresorbability improve outcomes? Ann Intern Med. 2016;164(11):775-6; corresponding author.
  15. Blumenthal RS, Gluckman TJ, Martin SS. Trends in the use of moderate-intensity to high-intensity statin and nonstatin lipid-lowering therapy: Turning off the faucet is much more valuable than mopping up the floor. JAMA Cardiol. 2017;2(4):355-356.

 

Letters [LE]

  1. Martin SS, Hollingsworth CL, Norfolk S, Wolfe CR, Hollingsworth JW. Pandemic H1N1 and cardiac dysfunction. 2011;139:1546.
  2. Clough JD, Martin SS, Cope MW. Sensitive troponin I assay in patients with suspected acute coronary syndrome. 2011;306:488.
  3. Martin SS, Jones SR. Lipid parameters and cardiovascular events in patients taking statins. 2012;308:131-2; corresponding author.
  4. Martin SS, Blaha MJ, Jones SR. Nonfasting lipids: there is the population and then there is the patient. JAMA Intern Med. 2013;173:935-6; corresponding author.
  5. Jones SR, Martin SS, Brinton E. Letter by Jones et al regarding article, “elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation”. 2014;129:e655.
  6. Joshi PH, Blaha MJ, Martin SS, Blumenthal RS. Letter regarding article, “Taking a longer term view of cardiovascular risk: the causal exposure paradigm”. 2014; available at http://www.bmj.com/content/348/bmj.g3047?tab=responses
  7. Martin SS, Li Y, Spertus JA, Jones SR. Response to letter by Dr. Lin regarding article, “HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative”. Eur Heart J. 2014; available at http://eurheartj.oxfordjournals.org/content/early/2014/06/28/eurheartj.ehu264/reply#ehj_el_2202; corresponding author.
  8. Khokhar AA, Martin SS, Joshi PH, Jones SR. “The HDL story is not over yet”; Letter regarding article, “Not so good cholesterol”. 2014; available at http://www.bmj.com/content/349/bmj.g4664/rr/763210
  9. Michos ED, Martin SS, Blumenthal RS. Response to the Letter Regarding Article, “Bringing Back Targets to ‘IMPROVE’ Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?”. Circulation. 2016 Mar 29;133(13):e462.
  10. Eatz T, Blumenthal RS, Stone NJ, Martin SS. Letter Regarding Critical Flaws in “Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review”. BMJ Open.

2016 Aug 11. http://bmjopen.bmj.com/content/6/6/e010401/reply#bmjopen_el_9932

  1. Eatz T, Blumenthal RS, Stone NJ, Martin SS. In Response to Vos and Ravnskov et al. BMJ Open. 2016 Oct 11. http://bmjopen.bmj.com/content/6/6/e010401/reply#bmjopen_el_9932
  2. Plante TB, Appel LJ, Martin SS. Critical Flaws in the Validation of the Instant Blood Pressure smartphone app-A letter from the app developers-Reply. JAMA Intern Med. 2016;176:1410-1.
  3. Driver S, Martin SS, Gluckman TJ, Clary JM, Blumenthal RS, Stone NJ. Reply: Lipid measurements: Fasting or nonfasting, women or men. J Am Coll Cardiol. 2016;68:1710-1711.
  4. Plante TB, Martin SS. Wearable technology and long-term weight loss. JAMA. 2017;317(3):318-319; corresponding author.

Case Reports [CR]

  1. Martin SS. Medulloblastoma and Mike. W&L J Science. 2003;5:27-32.
  2. Martin SS, Hollingsworth CL, Norfolk S, Wolfe CR, Hollingsworth JW. Reversible cardiac dysfunction associated with pandemic-2009-H1N1 influenza A. 2010;137:1195-7.
  3. Martin SS, Karra R, Mark DB. Pheochromocytoma presenting as fever of unknown origin. Am J Med. 2011;124:e5-6.
  4. Martin SS. Biatrial thrombus across a patent foramen ovale with fatal pulmonary and coronary embolism. J Echocardiogr. 2012;10:77-8.
  5. Catania J, Martin SS, Corey GR, Sexton DS. Diagnostic dilemma in a returning traveler with fever. Diagn Microbiol Infect Dis. 2013;77:85-6.
  6. Feldman DI, Martin SS, Blumenthal RS, Deune EG. Carpal tunnel syndrome in the digital era – Are electronic health records and wrist pedometers potentially synergistic risk factors? J J Physical Rehab Med. 2015, 1(2):010.
  7. Lawrence D, Salimian K, Leucker T, Martin SS. Uncommon presentation, rare complication and previously undescribed oncologic association of pheochromocytoma; the great masquerader. BMJ Case Rep. 2018; Apr 5;2018. pii:

bcr-2017-223993. doi: 10.1136/bcr-2017-223993.

 

Book Chapters [BC]

  1. Martin SS, Blumenthal RS, Miller M. LDL: Lower the Better. In: Fuster V, Narula J, editors. Coronary Risk Factor Update (Medical Clinics of North America). Philadelphia: Elselvier, 2012.
  2. Martin SS, Joshi PH, Jones SR. Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.  In: Lyons TJ, Toth PP, eds. Lipoproteins in Diabetes Mellitus. New York: Springer-Humana, 2012.
  3. Patel C, Blumenthal RS, Martin SS. Lipid-Modifying Therapy. In: Bhatt D, ed. Atherothrombosis in Clinical Practice.

Oxford: Oxford University Press, 2013.

  1. Martin SS, Blumenthal RS. Disorders of Lipid Metabolism. In: Aronow WS, Fleg JL, Rich MW, editors.

Cardiovascular Disease in the Elderly, 5th Edition. London: Informa Healthcare, 2013.

  1. Martin SS, Johnson A, Blumenthal RS. Use of high sensitivity C-reactive Protein for Risk Assessment. In: Ballantyne C, editor. Clinical Lipidology: a Companion to Braunwald’s Heart Disease, 2nd Elsevier: Amsterdam, Netherlands, 2013.
  2. Yousuf O, Martin SS, Whelton SP, Blumenthal RS. Inflammation and CAD: Use of hs-C-Reactive Protein as a Diagnostic and Prognostic Tool. Cardiology: Clinical Decision Support in Medicine. Wilmington, Delaware, 2013.
  3. Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND. Focused update on the 2013-2014 cardiovascular disease prevention guidelines. In: Blumenthal R, ed. 2014 Update to Preventive Cardiology: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: W.B. Saunders, 2014.
  4. Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. In: Zipes D, Braunwald E, eds. 2014 Update Braunwald’s Heart Disease. Philadelphia, PA: W.B. Saunders, 2014.
  5. Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. In: Blumenthal R, ed. 2014 Update to Preventive Cardiology: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: W.B. Saunders, 2014.
  6. Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk. In: Blumenthal R, ed. 2014 Update to Preventive Cardiology: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: W.B. Saunders, 2014.
  7. Cheng HG, Martin SS, Jones SR. Novel biomarkers and risk factors. In: Wong N, Amsterdam E, Blumenthal RS, eds. ASPC Primer of Preventive Cardiology. Demos Medical Publishing, New York, NY, 2014.
  8. Martin SS, Joshi PH, Michos ED. Lipids in coronary heart disease: From epidemiology to therapeutics. In: Aronow WS, McClung JA, eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment. Waltham, Mass.: Elsevier, 2015.
  9. Michos ED, Blaha MJ, Martin SS, Blumenthal RS. Screening for atherosclerotic cardiovascular disease in asymptomatic individuals. In: de Lemos J, Omland T, eds. Chronic Coronary Artery Disease: A Companion to Braunwald’s Heart Disease. Maryland Heights, MO: Elsevier, 2016.
  10. Ali M, Martin SS. Disorders of Lipid Metabolism. In: Aronow WS, Fleg JL, Rich MW, editors. Cardiovascular Disease in the Elderly, 6th London: Informa Healthcare, 2017.
  11. Sathiyakumar V, Jones SR, Martin SS. Xanthomas and lipoprotein disorders. In: Kang S, ed. Fitzpatrick’s Dermatology in General Medicine, 9th New York, New York: McGraw-Hill, 2018.

On-Line/Newsprint Articles and Case Discussions [OL]

  1. Martin SS, Horne A, Blumenthal RS. Who Should Get Statins for Primary Prevention? CardioSource. November 2011.

http://www.cardiosource.org/Science-And-Quality/Expert-Opinions-and-Cases/Hot-Topics/Who-Should-GetStatins-for-Primary-Prevention.aspx

  1. Martin SS, Blumenthal RS. SATURN and AIM-HIGH: ‘Back down to planet Earth’. Cardiology Today. November 2011. http://www.cardiologytoday.com/view.aspx?rid=89582
  2. Martin SS. The lipids/risk tightrope: 10 steps to optimize risk while we wait for the NCEP ATP IV guidelines. Consultant Live. July 2012. http://www.consultantlive.com/display/article/10162/2090976
  3. Martin SS, Blaha MJ, Blumenthal RS. Let’s not be so quick to stop statins: Expert opinion on the importance of awareness of reporting bias and outstanding questions in studies. Cardiology Today. October 2012.

http://www.healio.com/cardiology/vascular-medicine/news/print/cardiology-today/%7B3b6a1c09-bb29-4078a59e-5a7d8f492922%7D/lets-not-be-so-quick-to-stop-statins

  1. Martin SS. AHA Conference Blog. Cardiology Today. January 2013. http://www.healio.com/cardiology/practicemanagement/news/print/cardiology-today/%7Bec7662ab-a7af-498d-ba9c-0f3db3b55e53%7D/aha-conference-blogtempered-enthusiasm-for-novel-approaches-to-address-cholesterol
  2. Martin SS, Blumenthal RS. The wait is over: The new cholesterol treatment guidelines are here. Cardiology Today. November 2013. http://www.healio.com/cardiology/chd-prevention/news/online/%7B8351efe3-7cb7-42e1-bb06e70ee6ab5c62%7D/the-wait-is-over-the-new-cholesterol-treatment-guidelines-are-here
  3. Miller PE, Elshazly MB, Jones SR, Martin SS. Is Direct Measure of LDL Preferred Over a Calculated LDL? CardioSource. November 2013. http://biomarkers.cardiosource.org/Ask-the-Expert/2013/11/Is-Direct-Measure-ofLDL-Preferred-Over-a-Calculated-LDL.aspx
  4. Martin SS. How about a worldwide effort to collaborate on developing guidelines? CardioSource. November 2013.

http://cardiometabolic.cardiosource.org/Hot-Topics/2013/11/How-About-a-Worldwide-Effort-to-Collaborate-onDeveloping-Guidelines.aspx

  1. Martin SS. The Best Way to Spend a Morning at AHA? CardioExchange. November 2013.

http://www.cardioexchange.org/fellowship-training/aha-poster-sessions-is-there-a-better-way-to-spend-a-morning/

  1. Martin SS. 13: Good until the End. CardioExchange. November 2013.

http://www.cardioexchange.org/fellowship-training/aha-13-good-until-the-end/

  1. Martin SS. CardioExchange. Livetweeting at combined AHA.13/NEJM session on cardiovascular screening in young athletes. November 2013.
  2. Martin SS. Speakers highlight, debate approaches to CV risk assessment. Cardiology Today. November 2013.

http://www.healio.com/cardiology/chd-prevention/news/online/%7B7761c5d2-f1e2-4b25-9441-

7dc031091025%7D/blog-speakers-highlight-debate-approaches-to-cv-risk-assessment

  1. Jones SR, Martin SS. Derivation and validation of a novel method for more accurate estimation of LDL-C from the standard lipid profile. CardioSource. December 2013. http://ldl.cardiosource.org/Article-of-the-

Month/2013/10/Derivation-and-Validation-of-a-Novel-Method-for-More-Accurate-Estimation-of-LDL-C.aspx

  1. Martin SS, Stone NJ, Blumenthal RS. The risk discussion: A key virtue of the 2013 ACC/AHA cholesterol treatment guidelines. Cardiology Today. January 2014. http://www.healio.com/cardiology/practice-

management/news/online/%7Bb672ff07-1288-4fee-9407-82cb3821a8c9%7D/the-risk-discussion-a-key-virtue-ofthe-2013-accaha-cholesterol-treatment-guidelines

  1. Martin SS. STABILITY: Darapladib misses primary endpoint in stable CHD population. Cardiology Today. March 2014. http://www.healio.com/cardiology/highlights-from-acc-scientific-sessions-2014/stability-darapladib-missesprimary-endpoint-in-stable-chd-population
  2. Martin SS, Fang JC. Case: Assessment of Cardiac Risk and Need for Preventive Medications. CardioExchange. April 2014. http://www.cardioexchange.org/discussion/case-assessment-of-cardiac-risk-and-need-for-preventivemedications/
  3. Joshi PH, Martin SS, Blumenthal RS. The fascinating story of PCSK9 Inhibition: Insights and perspective from ACC.14. Cardiology Today. May 2014. http://www.healio.com/cardiology/chd-prevention/news/print/cardiologytoday/%7Bd531fcd9-ea52-4230-b412-da9270344fff%7D/the-fascinating-story-of-pcsk9-inhibition-insights-andperspective-from-acc
  4. Houston B, Martin SS. Hot, cool, cold: the future of phospholipase A2 as a therapeutic target for CHD. Cardiology Today. July 2014. http://www.healio.com/cardiology/chd-prevention/news/print/cardiology-today/%7B35f31d9ea1ef-469f-9a40-18b98c685eed%7D/hot-cool-cold-the-future-of-phospholipase-a-2-as-a-therapeutic-target-for-chd
  5. Feldman DI, Martin SS. Is LDL-C measurement better than estimating absolute risk for treating increased cholesterol? CardioSource. July 2014. http://biomarkers.cardiosource.org/Ask-the-Expert/2014/07/Is-LDLCMeasurement-Better-Than-Estimating-Absolute-Risk.aspx
  6. Ashen MD, Blumenthal RS, Martin SS. A young man with a history of myocardial infarction and low HDL-C. CardioSource. August 2014. http://ldl.cardiosource.org/Case-Challeges/2014/08/A-Young-Man-With-a-History-ofMyocardial-Infarction-and-Low-HDL-C.aspx
  7. Ahmed HM, Martin SS. Statin use and physical activity: the importance of confounding. CardioSource. August 2014.

http://ldl.cardiosource.org/Article-of-the-Month/2014/08/Statin-Use-and-Physical-Activity.aspx

  1. Martin SS. MY APPROACH to Patients Intolerant of Statins. Practice Update. September 2014.
  2. Martin SS. Ideas Lost, But Not Stolen. CardioExchange. March 2014. http://www.cardioexchange.org/fellowshiptraining/ideas-lost-but-not-stolen/http://www.practiceupdate.com/ExpertOpinion/1180/1/2
  3. Martin SS, Fang JC. An Electrophysiology Service Diagnostic Conundrum. CardioExchange. August 2014.

http://www.cardioexchange.org/discussion/an-electrophysiology-service-diagnostic-conundrum/

  1. Martin SS, Blumenthal RS. Applying wisdom from Pearl Jam to LDL, IMPROVE-IT. Cardiology Today. December
  2. http://www.healio.com/cardiology/vascular-medicine/news/online/%7B49b7ac76-8cfc-44b4-a38d-

7225a672aae0%7D/commentary-applying-wisdom-from-pearl-jam-to-ldl-improve-it

  1. Martin SS, Blumenthal RS. An in-depth look at the IMPROVE-IT trial. Cardiology Today. December 2014.

http://www.healio.com/cardiology/practice-management/news/online/%7Bda56fbe8-443c-4a19-a608-

776159fbc540%7D/commentary-an-in-depth-look-at-the-improve-it-trial

  1. Achirica MC, Martin SS. CV risk management of a young asymptomatic adult with a ‘high-risk lifestyle. http://www.acc.org/. Cardiometabolic Commmunity. December 2014. http://www.acc.org/education-andmeetings/patient-case-quizzes/cv-risk-management-of-a-young-asymptomatic-adult-with-a-high-risklifestyle?w_nav=LC
  2. Florido R, Blumenthal RS, Martin SS. Insights into statin-associated diabetes: How important is the risk and how should you counsel your patient? http://www.acc.org/. Cardiometabolic Community. January 2015.

http://www.acc.org/latest-in-cardiology/articles/2015/01/06/08/57/insights-into-statin-associateddiabetes?w_nav=TI

  1. Santos RD, Martin SS. Hypercholesterolaemia. BMJ Best Practice. Updated annually since 2014. http://bestpractice.bmj.com/best-practice/monograph/170/resources/credits.html
  2. Martin SS, Blumenthal RS. Statin therapy and acute memory impairment. Practice Update. July 2015.

http://www.practiceupdate.com/c/26134/1/2

  1. Wong ND, Blaha M, Al-Mallah MH, DeFilippis AP, Martin SS, Miedema MD, Scott R. Ask the experts: What practice changes have you made based on the risk/prediction/cholesterol guidelines? http://www.acc.org/. July 22, 2015.

Accessed August 24th, 2015. http://www.acc.org/latest-in-cardiology/articles/2015/07/21/11/18/ask-the-expertswhat-practice-changes-have-you-made-based-on-the-risk-prediction-cholesterol-guidelines

  1. Al Danaf JA, Martin SS, Blumenthal RS. Ezetimibe: The lower the LDL-C, the better (even for total cardiovascular events). http://www.acc.org/. March 9, 2016. http://www.acc.org/latest-in-

cardiology/articles/2016/03/09/06/50/ezetimibe-the-lower-the-ldlc-the-better?w_nav=LC

  1. Martin SS, Byrne K. Hypertriglyceridemia-induced pancreatitis during pregnancy. http://www.acc.org/. March 15, 2016.

http://www.acc.org/education-and-meetings/patient-case-quizzes/hypertriglyceridemia-induced-pancreatitis-duringpregnancy?w_nav=LC

  1. Plante TB, Martin SS. App Review: The ACC-AHA ASCVD risk estimator. Practical Cardiology.

http://practicalcardiology.modernmedicine.com/practical-cardiology/news/app-review-acc-aha-ascvd-risk-estimator

  1. Plante TB, Martin SS. App Review: QuitGuide. Practical Cardiology. May 31, 2016.

http://practicalcardiology.modernmedicine.com/practical-cardiology/news/app-review-month-quitguide

  1. Aronis KN, Blumenthal RS, Martin SS. Summarizing the Current State and Evidence on Efficacy and Safety of Statin Therapy. http://www.acc.org/. November 17, 2016. http://www.acc.org/latest-in-

cardiology/articles/2016/11/17/09/03/summarizing-the-current-state-and-evidence-on-efficacy-and-safety-of-statintherapy?w_nav=TI

  1. Oren O, Okada DR, Blumenthal RS, Martin SS. Momentum builds for PCSK9 inhibition at ACC.17: Even lower LDL-C is even better. http://www.acc.org/. May 11, 2017. http://www.acc.org/latest-incardiology/articles/2017/05/08/13/13/momentum-builds-for-pcsk9-inhibition-at-acc17
  2. Marvel FA, Wang J, Lee M, Spaulding E, Merali F, Yang W, Chau Ly B, Martin SS. Reinventing acute MI recovery: Story of the Johns Hopkins Corrie Digital Health project. Cardiology Today. July 2017.

https://www.healio.com/cardiology/vascular-medicine/news/print/cardiology-today/%7Bf740785b-2ea4-49e8-

83ac-d79d9b1a5cec%7D/reinventing-acute-mi-recovery-story-of-the-johns-hopkins-corrie-digital-health-project

  1. Vaishnav J, Mody FV, Martin SS, Blumenthal RS. Cardiovascular Risk Assessment & Prevention in Patients With HIV: Should We Be More Aggressive With Statin Therapy in this Special Population? May 19, 2017. http://www.acc.org/latest-in-cardiology/articles/2017/05/18/14/07/cv-risk-assessment-and-prevention-in-patientswith-hiv
  2. Whelton SP, Mody FV, McEvoy JW, Martin SS, Blumenthal RS. Cardiovascular Risk Assessment and Allocation of Lipid-Lowering Therapy in Patients with Chronic Inflammatory Diseases. June 29, 2017. http://www.acc.org/latestin-cardiology/articles/2017/06/29/08/22/cv-risk-assessment-and-allocation-of-lipid-lowering-therapy-in-patientswith-chronic-inflammatory-diseases
  3. Ali M, Blumenthal RS, Martin SS. Analysis of the 2017 NLA Statement on PCSK9 Inhibitor Therapy. Aug 7, 2017.

https://www.acc.org/latest-in-cardiology/articles/2017/08/03/13/15/analysis-of-the-2017-nla-statement-on-pcsk9inhibitor-therapy

  1. Kapoor K, Martin SS, Blumenthal RS. Simulation of Lipid-Lowering Therapy Intensification in a Population with Atherosclerotic Cardiovascular Disease: A Case for Improved Guideline Adherence. Aug 18, 2017. http://www.acc.org/latest-in-cardiology/articles/2017/08/17/10/00/simulation-of-lipid-lowering-therapyintensification-in-a-population-with-acd
  2. Hamo CE, Whelton SP, Blumenthal RS, Martin SS. Reported LDL-C May Not Be as Low as You Think.

http://www.acc.org/. October 13, 2017. http://www.acc.org/latest-in-cardiology/articles/2017/10/12/11/22/itappears-that-reported-ldl-c-may-not-be-as-low-as-you-think

  1. Cordoso R, Vaishnav J, Martin SS, Blumenthal RS. How Low Should We Decrease LDL-Cholesterol in a CostEffective Manner? Feb 16, 2018. http://www.acc.org/latest-in-cardiology/articles/2018/02/16/09/31/how-lowshould-we-decrease-ldl-cholesterol-in-a-cost-effective-manner
  2. Pallazola V, Sathiyakumar V, Martin SS, Blumenthal RS. Optimizing Non-Fasting Lipid Analysis in the Era of Precision Medicine. Mar 21, 2018. https://www.acc.org/latest-in-cardiology/articles/2018/03/21/08/51/optimizingnon-fasting-lipid-analysis-in-the-era-of-precision-medicine
  3. Jones R, Arps K, Davis DM, Blumenthal RS, Martin SS. Clinician Guide to the ABCs of Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Apr 2, 2018. https://www.acc.org/latest-incardiology/articles/2018/03/30/18/34/clinician-guide-to-the-abcs
  4. Hla D, Jones R, Blumenthal RS, Martin SS. Assessing Severity of Statin Side Effects: Fact Versus Fiction. Apr 9,
  5. https://www.acc.org/latest-in-cardiology/articles/2018/04/09/13/25/assessing-severity-of-statin-side-effects 48. Pallazola V, Hla D, Arvanitis M, Blumenthal RS, Martin SS. Major Dyslipidemia Guidelines and Their Discrepancies: A Need for Consensus. Apr 24, 2018. https://www.acc.org/latest-in-cardiology/articles/2018/04/24/08/56/majordyslipidemia-guidelines-and-their-discrepancies
  6. Hla D, Cardoso R, Blumenthal RS, Martin SS. Managing Dyslipidemia in Primary Prevention. May 7, 2018.

https://www.acc.org/latest-in-cardiology/articles/2018/05/07/14/41/managing-dyslipidemia-in-primary-prevention

  1. Brown E, Byrne K, Jones SR, Martin SS. Genetic Testing in Dyslipidemias. May 16, 2018.

https://www.acc.org/latest-in-cardiology/articles/2018/05/15/08/31/genetic-testing-in-dyslipidemias

Educational Material for Patients and Lay Public [EM]

  1. Martin SS, Blumenthal RS. Addressing the Debate: Who Should Take Statins? org. 2012.

http://www.cardiosmart.org/News/Default.aspx?id=3987

  1. Martin SS. HDL – The Good Cholesterol? Yahoo Heart-Smart Living. http://health.yahoo.net/experts/heartsmartliving/hdl-good-cholesterol
  2. Swiger KJ, Martin SS. Statins and the Brain. Yahoo Heart-Smart Living.

http://health.yahoo.net/experts/heartsmartliving/statins-and-brain-drs-seth-martin-and-kristopher-swiger-0

  1. Martin SS, Dahagam C. Sugar and Your Heart: the Not-So-Sweet Truth. S. News and World Report. 2015.

http://health.usnews.com/health-news/patient-advice/articles/2015/11/11/sugar-and-your-heart-the-not-so-sweettruth

  1. Martin SS, Plante TB. How to Pick Your Next Health App. S. News and World Report. 2016.

http://health.usnews.com/health-news/patient-advice/articles/2016-04-28/how-to-pick-your-next-health-app

  1. Eatz T, Blumenthal RS, Martin SS. Patients and Clinicians Unite Part One: The ABCs of Heart Disease. S. News and World Report. 2017. http://health.usnews.com/health-care/for-better/articles/2017-03-22/patients-and-cliniciansunite-part-one-the-abcs-of-heart-disease
  2. Eatz T, Blumenthal RS, Martin SS. Patients and Clinicians Unite Part Two: Tailored Treatment is the Best Fit. S. News and World Report. 2017. http://health.usnews.com/health-care/for-better/articles/2017-03-22/patients-andclinicians-unite-part-two-tailored-treatment-is-the-best-fit
  3. Jung J, Silverman-Lloyd L, Martin SS. Replacing Bad Habits with Good Ones: Living Heart-Healthy and Happy. S. News and World Report. 2017. https://health.usnews.com/health-care/for-better/articles/2017-09-22/replacing-badhabits-with-good-ones-living-heart-healthy-and-happy
  4. Eatz T, Okada DR, Martin SS. The New Year Is Here, So Get on Your Feet and Dance! S. News and World Report. 2018. https://health.usnews.com/health-care/for-better/articles/2018-01-31/the-new-year-is-here-so-get-on-yourfeet-and-dance
  5. Jung J, Martin SS. Learning the Lingo: Decoding Your Cardiologist. S. News and World Report. 2018.

https://health.usnews.com/health-care/for-better/articles/2018-04-18/learning-the-lingo-decoding-your-cardiologist

Media Releases or Interviews [MR]

10/1/13 Reporter Alice Park. “Statins Drugs Linked to Lower Risk of Cognitive Decline,” in TIME; quoted in article
3/2/16  Interviewed by Reporter Jennifer Gilbert on FOX 45 Baltimore, “Statins May Not Harm Memory”; 2 minute live interview
11/26/13 Reporter Gina Kolata. “Bumps in the Road to New Cholesterol Guidelines,” in The New York Times, page A17 in print, and also online; quoted in article
7/25/15 Reporter Andrew Pollack. “New Drug Sharply Lowers Cholesterol, but It’s Costly,” in The New York Times, page B1 in print, and also online; quoted in article
12/14/15 Reporter Megan Scudellari. “Doctors’ texts can spur patients to exercise,” in The Boston Globe, Health and Wellness section, and online; quoted in article
6/9/15  Reporter Alice Park. “The Next Big Drug to Treat Heart Disease,” in TIME; quoted in article.
3/2/16  Interviewed by Reporter Megan Pringle on WBAL-TV Chanel 11 Baltimore, “Blood Pressure App Not

Effective, Study Finds”
6/20/16 Reporter Nathan Olivarez-Giles. “Google Sharpens Search Results for ‘Skin Rash,’ ‘Tummy Ache’ and Other Symptoms,” in The Wall Street Journal; quoted in article
6/23/17 Reporter Meredith Cohn. “Heart Healthy Diet as Effective as Statins, American Heart Association Says,” The Baltimore Sun, in print and online; quoted in article
2/27/18 Reporter Tori Rodriguez. “Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time,” Cardiology Advisor, online; quoted in article
3/10/18 Reporter Michael O’Riordan. “ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit,” TCTMD, online; quoted in article
4/16/18 Reporter Jane E. Brody. “Weighing the Pros and Cons of Statins,” in The New York Times, page D5 in print, and also online; quoted in article

FUNDING

EXTRAMURAL Funding

Research Extramural Funding – Current

12/22/15 – 12/21/20    CASCADE-FH Registry

                          990034
                          FH Foundation
                          $25,000
                         

 

 National PI: Joshua Knowles

Role: Site PI, 1%; national, multi-center initiative to track therapy and outcomes over time in an effort to further the knowledge and understanding of the disease and improve the care, quality of life, and survival of those with familial hypercholesterolemia. 
3/31/16 – 3/30/19 Advances in Precision Medicine through the Very Large Database of Lipids
                          80039075
                          The David and June Trone Family Foundation
                          $1,700,000
                         

 

 PI: Steven R. Jones

Role: Co-PI, 20%; this is the 2nd harvest of this big data study after a successful series of studies on LDL-C accuracy and other clinical problems. 
5/1/16 – 4/30/19 Variability in Clinician-Patient Risk Discussions for Using Statins in Primary Prevention and Association with Statin Prescription
                          42182
                          American Heart Association
                          $149,163
                         

 

 PI: Jeffrey Clough

Role: Co-I, in kind; Consultant to Duke team on shared-decision making process for statins.
9/1/17 – 8/31/18 Johns Hopkins Ciccarone – Aetna mHealth Center of Excellence: Training Core
                          18032293
                          Aetna Foundation
                         

 

 $175,000

Role: PI, 20%; this project supports mHealth education and career development within the Ciccarone Center and the greater Johns Hopkins Community.
7/31/17 – 6/30/20 mHealth in Pulmonary Arterial Hypertension
                          R34 – notice of award received; award being processed
                          NIH/NHLBI
                          $450,000
                          PI: Evan Brittain
                         

 

 Role: Consultant, 5%; we aim to extend use of the mActive mobile health intervention to increase physical activity in the pulmonary arterial hypertension population.
10/30/17 – 8/31/18 Expansion of Corrie Digital Health Platform to Reading Hospital
                          90076469
                          Reading Hospital Foundation
                          $35,000

Role: PI, 5%; this project supports piloting of the Corrie Digital Health Platform for acute myocardial infarction patients at Reading Hospital in Pennsylvania, a JHCRN site.

1/2/18 – 1/1/19          Prevalence of Familial Chylomicronemia Syndrome 

                                   Notice of award received; award being processed (IRB approved: IRB00150254)

                                    Akcea Therapeutics

                                    $20,000

Role: PI, 5%; the purpose of this project is to perform an electronic medical records search to investigate the prevalence of Familial Chylomicronemia Syndrome (FCS) as part of a national effort to better establish the prevalence of this rare and difficult to manage lipid disorder.

Research Extramural Funding – Previous

7/1/13 – 6/30/15 Johns Hopkins Cardiovascular Disease Epidemiology Training Program
             T32 HL007024
                          NIH/NHLBI
                          $165,000
                          PI: Josef Coresh
                         

 

 Role: trainee, 100%; established in 1975, the program focuses on interdisciplinary training on the epidemiology of the leading cause of death in the United States. The program integrates knowledge on all aspects of cardiovascular disease: biology, behavior, treatment and prevention. Training emphasizes a collaborative approach and active participation in research on cohort studies and clinical trials.
4/1/15 – 6/30/16 Long-Term Follow-up of mActive Trial Participants
             90071407
                          Aetna Foundation and Fitbug
                          $250,000
                         

 

 Role: PI, 20%; to evaluate the long-term effects of mobile health interventions on physical  activity in adult smartphone users followed in ambulatory cardiology clinics.
7/1/15 – 6/30/16 Real-Time Association of Physical Activity and Smoking Urges
             77623
                          AHA ATRAC
                          $150,000
                          PI: Michael Blaha
                         

 

 Role: Co-I, 7%; to examine the real-time association between physical activity and smoking  urges, and thereby better inform public messaging by the FDA.
9/15/15 – 6/30/17 Pollin Transformative Research Program in Preventive Cardiology
             80004734
                          Pollin Cardiovascular Research Fund
                          $10,000,000
                          PI: Roger Blumenthal
                         

 

 Role: Co-I, 5%; in support of Dr. Roger Blumenthal and colleagues in the Ciccarone Center to advance the field of preventive cardiology.
6/30/16 – 8/31/17 Targeting Smoking Cessation in Underserved Baltimore (mActive-Smoke)
                          16-1580
                          Aetna Foundation
                         

 

 $219,000

Role: PI, 20%; this project is harnessing novel mobile health methods to evaluate the role of physical activity in smoking urges.
9/15/15 – 12/31/17 Impact of Google Health Search on Clinical Encounters
                          88552
                          Google
                          $168,000

                                   PI: Martin, 10%; we aim to understand the diagnostic accuracy of Google Health Search and its                                         impact on a patient’s encounter with his or her health care provider.

2/3/17 – 2/2/18           Pilot Study of Digital and Mobile Health Technology in Heart Failure Care and Patient Activation

                                    135748

                                   Stanford Med X / Nokia

                                    $22,500

Role: PI, in kind; this project is part of the Stanford Med X Everyone Included competition.

System Innovation or Quality Improvement Extramural Funding – Current

8/1/16 – 6/30/19         MiCORE Study: Evaluating the First Cardiology CareKit Application

                                    99938

                                    Apple

                                    $71,750 (205 Apple Watches)

                                       Role: PI, 1%; this project is evaluating the Corrie digital health platform in acute myocardial                                         infarction recovery.

System Innovation or Quality Improvement Extramural Funding – Previous

7/1/16 – 6/31/17 Creation of the First Cardiology CareKit Application
             110934
                          Wallace H. Coulter Translational Research Partnership
                         

 

 $25,000

Role: PI, 1%; in support of initial iOS development.
8/15/16 – 8/14/17 Corrie Health Platform Blood Pressure Integration
                          99938
                          iHealth
                          $10,000
                         

 

 Role: PI, 1%; to integrate an FDA-approved Bluetooth enabled blood pressure device with the Corrie digital health platform.
5/15/17 – 2/14/18 Corrie Digital Health Platform: Reinventing Cardiac Recovery
                          90073496
                          TEDCO Maryland Innovation Initiative
                          $115,000

                                       Role: PI, 8%; we aim to develop and pilot test a digital platform that improves the hospital discharge process, improves adherence, and prevents adverse outcomes (e.g. readmissions).

CLINICAL ACTIVITIES

Clinical Focus

Annually I attend six weeks on the inpatient General Cardiology Service and 10 days on the Janeway ACS Service. In the outpatient setting, I serve as Director of the Ciccarone Advanced Lipid Disorders Clinic. The multidisciplinary clinic involves a dietitian, genetic counselor, nurse practitioner, and the specialty pharmacy. The clinic has seen substantial growth under my leadership, with multiple daily referrals from around the country and internationally. We care for patients with genetic dyslipidemias, including familial hypercholesterolemia, familial combined hyperlipidemia, and familial hypertriglyceridemia, as well as patients with statin intolerance, HDL disorders, and elevated Lp(a). 

Certifications

2011 Maryland Board of Physicians: D72547

2011 American Board of Internal Medicine: Internal Medicine

2015 American Board of Internal Medicine: Cardiovascular Disease

Clinical (Service) Responsibilities

2015-present        Attending Physician, General Cardiology Service, Johns Hopkins Hospital, 15%

2015-present        Attending Physician, General Cardiology Clinic, Johns Hopkins Outpatient Center, 5%

2015-present       Attending Physician, Advanced Lipid Disorders Clinic, Johns Hopkins Outpatient Center, 10% 2016-present        Attending Physician, Janeway ACS Firm, Osler Medicine Service, Johns Hopkins Hospital, 7.5%

Clinical Draw from outside local/regional area

  • Referrals from around the US, including VA, PA, DE, NJ, FL, CA, IL, as well as a variety of countries including England, Kuwait, and Russia               

Clinical Program Building / Leadership

2013-2014              Director, Cardiology Moonlighting Program

2015-2018              Co-Director, Advanced Lipid Disorders Program 2018-present          Director, Advanced Lipid Disorders Program

Clinical Demonstration Activities to external audience 

2015-                 Professor Freny Mody from University of California Los Angeles visited our Ciccarone Advanced               

   Lipid Disorders Clinic as part of her sabbatical, to learn from our clinical model

Contributions to Point-of-Care Clinical Guides for Physicians

  • Duke Internal Medicine Residency Survival Guide Cardiology Section
  • Johns Hopkins Osler Residency Survival Guide Lipid Management Section
  • Johns Hopkins Osler Residency Survival Guide Lipid Management Section
  • ACC/AHA ASCVD Risk Estimator App Contributor to beta testing & content

EDUCATIONAL ACTIVITIES

Educational Focus

As an Osler Medical Housestaff Training Program Firm Faculty Clinical Coach and Educator, I am paired with three interns and two JARs. For each intern, I observe 3 new patient interactions (H&P + counseling) and review 3 admission or progress notes over the course of the year. For each JAR, I review one admission note and observe one teaching rounds. I also attend faculty development sessions, firm grand rounds, social events, and actively participate in intern recruitment. Furthermore, I serve as a resource for my firm’s residents for career, research, and professional development advice.

Teaching  

Classroom instruction JHMI/Regional   

2012                 Lecturer, Osler Medical Residency Noon Conference, “Recommendations for the Adult Treatment Panel IV Guidelines: An Exercise in Evidence-Based Medicine,” Johns Hopkins Hospital, Baltimore MD

  • Guest Moderator, Osler Medical Residency Noon Conference, “Understanding the 2013 ACC/AHA Cholesterol Treatment Guidelines,” Johns Hopkins Hospital, Baltimore MD

2014-present  Lecturer, “Dyslipidemia and Cardiovascular Prevention,” annual interactive lecture to Johns Hopkins 

                          Preventive Medicine Residency, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  • Lecturer, Osler Medical Residency Noon Conference, Evidence-Based Medicine Debate Series, “2013

ACC/AHA Cholesterol Treatment Guidelines: Pros and Cons,” Johns Hopkins Hospital, Baltimore MD

2015                 Lecturer, “Heart Failure,” Introduction to the Biomedical Sciences [260.00], Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  • Small Group Leader for 20 medical students, Johns Hopkins School of Medicine, Cardiovascular Genes to Society Course, “Coronary Heart Disease,” Armstrong Education Building, Baltimore MD
  • Lecturer, Introduction to Biomedical Research and Careers I, II, III (Biophysics 250:106/300/306),

“Using Big Data: The Very Large Database of Lipids,” Johns Hopkins University, Baltimore, MD

2016                 Lecturer, Osler Medical Residency Noon Conference, PCSK9 Inhibitors: A New Era in Lipid Management,” Johns Hopkins Hospital, Baltimore MD

  • Lecturer, Cardiogenetics Case Conference, “It Takes Two: Homozygous for p.Val227Ala Variants in LPL,” Johns Hopkins Hospital, Baltimore MD
  • Lecturer, Hopkins Cardiology Fellows Noon Conference, “Lipid Management in 2017,” Johns Hopkins Hospital, Baltimore MD
  • Lecturer, Osler Medical Residency Noon Conference, “Lipid Management in 2017,” Johns Hopkins Hospital, Baltimore MD
  • Lecturer, Hopkins Cardiology Fellows Noon Conference, “Lipid Management in 2018,” Johns Hopkins Hospital, Baltimore MD

National             None

 

International        None

Clinical instruction

JHMI/Regional    

2014               Preceptor for 4 rotating groups of 4 medical students over the course of a half day, Johns Hopkins

School of Medicine, Cardiovascular Genes to Society Course, “Examination of Patients with Valvular Heart Disease,” Johns Hopkins Hospital, Baltimore MD

2014                 Co-Leader of Vascular Access Training, Osler Medical Residency, “Osler Intern Procedure Training Day in Simulation Lab,” Johns Hopkins Hospital, Baltimore MD

2015-present       Attending, Ciccarone Advanced Lipid Disorders Clinic, weekly bedside teaching of cardiology fellows, endocrinology fellows, medicine residents, and students, Johns Hopkins Hospital, Baltimore MD

2015-present      Attending, Inpatient General Cardiology Service and Janeway ACS Service, 2 months per year, bedside                                teaching of cardiology fellows, medicine residents, and students, Johns Hopkins Hospital, Baltimore MD;                                 quotes from trainees: “Dr. Martin provided some of the most teaching on rounds that I have had by any                               attending. He takes the time to provide his rationale for decision-making.”; “Dr. Martin was always eager                            to teach and discuss patients/interesting findings.”; “He was very approachable and supportive when we                            were busy.”; “great teacher, fights for his residents”

2014                 Faculty preceptor for 3 medical students on patient history taking and physical examination, and H&P write-ups, Johns Hopkins School of Medicine, Cardiovascular Genes to Society Course, “Transition to the Wards,” Johns Hopkins Hospital, Baltimore MD

2016               Faculty preceptor for 4 rotating groups of 4 medical students over the course of a half day, Johns

Hopkins School of Medicine, Cardiovascular Genes to Society Course, “Examination of Patients with Valvular Heart Disease,” Johns Hopkins Hospital, Baltimore MD

2016                Faculty moderator for 25 Internal Medicine residents, Johns Hopkins Bayview Medical Resident

“Morning Report,” Johns Bayview Medical Center, Baltimore MD

2016                Faculty participant for 8 Internal Medicine residents in discussion about career development, “Meet the

Giants,” Janeway Firm, Osler Medical Residency, Johns Hopkins Hospital, Baltimore MD

National             None

 

International        None

CME instruction JHMI/Regional

2015                Lecturer, Familial Hypercholesterolemia: Identifying Patients and Improving Outcomes, ACC Interactive 

                          CME Workshop, Johns Hopkins Hospital, Baltimore, MD

  • Speaker, PCSK9 Inhibitors: A New Era in Lipid Management, Suburban Cardiovascular Symposium,

                          Bethesda, MD

  • Lecturer, Diagnosing and Treating Statin Associated Muscle Symptoms: Focus on PCSK9 Inhibitors,

                          20th Annual Coastal Cardiac & Vascular Conference, Cambridge, MD

2018                  Lecturer, Mobile Health. Apps for You and Your Patients, 29th Annual Update in Cardiology, Christiana Care Health System, Newark, DE

 

National

2011                Lecturer, Recommendations for the Adult Treatment Panel IV, CardioCareLive

2011                Lecturer, Recommendations for the Adult Treatment Panel IV, MyCME

2011                Lecturer, Limitations in Friedewald LDL Cholesterol and a Simple Solution, BioConferenceLive

  • Speaker, 56 yo M w/ Abnormal Lipid Profile: Applying the 2013 CV Risk Guidelines, QuantiaMD
  • Speaker, Cardiovascular Controversies: Exploring the ACC and AHA Guidelines on the Treatment of

                          Blood Cholesterol, ReachMD

  • Speaker, Update on Dyslipidemia, 8th Annual Medical Education Conference, South Padre Island, TX
  • Lecturer, Assessment of LDL-C in the Modern Era: Using a More Accurate LDL-C Estimate to Inform Personalized Clinical Decision-Making, Quest National Webinar

2017               Lecturer, Science of PCSK9 and LDL-C Lowering Efficacy, VuMedi National Webinar Update on 

                          PCSK9 Inhibitors

 

International          

2017                  Lecturer, Management of Acute Coronary Syndromes: From Acute Management to Chronic Therapy, lecturers in Beijing, China and Hangzhou, China, as part of Academic ASCVD International Exchange CME Program

Mentoring

Pre-doctoral Advisees /Mentees

2016 – present    Jane Wang, [MD Candidate], Johns Hopkins University School of Medicine, Awarded a Dean’s Year of Research by the Johns Hopkins Department of Medicine to evaluate the educational component of the Corrie project. Co-authored articles RA 21, EO 25-26, OL 38.

2016 – present    Erin Spaulding, [PhD Candidate], Johns Hopkins University School of Nursing, Co-sponsor on her NRSA to study the process of user engagement with mobile health among adults following an acute myocardial infarction. Unconditional pass on her preliminary oral exam. Oral competition award in Johns Hopkins Cardiovascular Research Retreat. Co-authored OL 38.

2016 – present    Gavi Rawson, [Computer Science], Currently Summer internship at Apple on the CareKit and

ResearchKit teams, Cupertino, CA, followed by a Master’s in Computer Science at Columbia University, New York City, New York. Thrived as the first lead Corrie iOS developer.

  • – present Ryan Demo, [Computer Science], Senior undergraduate student in Computer Science at Johns Hopkins Whiting School of Engineering, accepted into Master’s program. Thriving as second lead Corrie iOS developer.
  • – present Lochan Shah, [MD Candidate], Johns Hopkins University School of Medicine, faculty mentor on her summer project, turned long-term project, focused on app usage in Corrie program.
  • – present Shannon Wongvibulsin, [MD PhD Candidate], Johns Hopkins University School of Medicine, Co-

sponsor on her F30 application to explore micro-randomization techniques in the Corrie project.

  • – present Daniel Weng, [MD Candidate], Johns Hopkins University School of Medicine, faculty mentor on his summer project focused on vital signs monitoring in Corrie program.

Post-doctoral Advisees / Mentees

  • – 2014      Mohammed B. Elshazly, MD, [Osler Medicine Resident], Currently Assistant Professor of Cardiology, Weill Cornell Medical College, Education City, Al Luqta St, Ar-Rayyan, Qatar. First-rate clinical scientist who working with me published 1st author papers in the top two cardiology journals, JACC and Circulation, and was a 2nd author on a JAMA paper. Went on to the prestigious Cleveland Clinic cardiology training program and has returned to his home in Qatar to join the cardiology faculty. Coauthored OR 15-17; OR 19; OR 36; OR 38; OR 51; EO 2; MT 1; OL 7.
  • – 2016      Elliott Miller, MD, [Osler Medicine Resident], Currently Critical Care Fellow, National Institutes of Health, Bethesda, MD, Productive clinician scientist with multiple 1st author papers and national scientific conference presentations, on lipids and atherosclerosis risk, before moving on to a critical care fellowship before cardiology fellowship. Co-authored OR 39; OR 45; OR 62; OR 64; EO 15; OL 7.

2013 – 2016     Kristopher J. Swiger, MD, [Osler Medicine Resident], Currently Cardiology Fellow, Vanderbilt University

Medical Center, Nashville, TN. An outstanding and highly productive clinician investigator who published 14 articles with me over 3 years, including a systematic review on statins and cognition that has been cited 113 times. Went on to a medicine faculty position at UNC, followed by cardiology fellowship at Vanderbilt where he continues to excel towards a bright career in academic medicine. Co-authored OR 18; OR 22; OR 27; OR 36-37; RA 12; EO 7; EO 13; EO 16-17; MT 1; EM 3.

2015 – 2017       Timothy B. Plante, MD MHS, [General Internal Medicine Fellow], Currently Assistant Professor of Medicine, The Robert Larner, M.D. College of Medicine at The University of Vermont, Burlington, VT. Mentored on one of the most well-known early mobile health studies, evaluating the IBP blood pressure app. That work was published in JAMA IM and was recognized with the W. Leigh Thompson Excellence in Clinical Research Fellow Award at the 2016 Hopkins DOM Research Retreat. Co-authored articles OR 46; EO 11; LE 12; LE 14; OL 34-35; EM 5.

  • – present Seamus Whelton, MD MPH, [Cardiology Fellow], Currently Assistant Professor of Medicine and

Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD. Prior Hopkins cardiology

fellow recruited to the faculty at Hopkins. Given his interest in lipidology, I have served as a clinical mentor to Dr. Whelton and a research mentor on a collaborative project between Hopkins and Mayo Clinic on LDL-C accuracy. Co-authored OR 69; RA 9; BC 6.

  • – present Renato Quispe, [Postdoc Fellow], Currently Internal Medicine Resident, Einstein/Montefiore

Department of Medicine, Bronx, New York. Joined from Peru for two years of training before residency. Was highly productive while obtaining an MHS degree, with multiple conference presentations including an oral presentation at AHA, multiple 1st author papers, Northwestern Young Investigator Award Competition Finalist, and 2016 Stanley L. Blumenthal, MD Cardiology Research Award. Co-authored OR 35-36; OR 38; OR 51; OR 55; OR 66; EO 14; EO 16-18. 

2015 – present  Vasanth Sathiyakumar, MD, [Osler Medicine Resident], An outstanding clinician investigator addressing

high impact questions in the Very Large Database of Lipids, resulting in multiple national presentations and first author presentations including two papers in Circulation. Recognized with the Daniel Baker Award for his extraordinary clinical performance as an Osler resident. Matched into Hopkins cardiology fellowship. Co-authored articles OR 70, 75; EO 24; BC 14.

2015 – present  Francoise A. Marvel, MD, [Assistant Chief of Service, Johns Hopkins Bayview Medical Center], Corrie Project Lead, emerging as a national leader in health care transformation through digital health tools. Completed an Armstrong Institute Patient Safety Leadership Academy Fellowship. Now serving in the prestigious role of chief resident. Matched into Hopkins cardiology fellowship. Co-authored articles OR 58; RA 17; EO 25-26; OL 38.

RESEARCH ACTIVITIES

Research Focus

My research is grounded in preventive cardiology, with a focus on multiple complementary areas including lipidology, cardiovascular risk assessment, mobile/digital health, big data, and precision medicine. I led the development of an algorithm for LDL cholesterol estimation that is now validated and being translated back into clinical practice. I am moving into the area of mobile/digital health with the long-term aim of improving outcomes in the prevention of cardiovascular disease.

Research Program Building / Leadership

The following portfolio of IRB-approved clinical research protocols involve multidisciplinary teams and reflect program building/leadership in lipidology and mobile/digital health.

07/12 – present   Very Large Database of Lipids (VLDL)                                                             

                            IRB00074308, Johns Hopkins Hospital

                            Role in Project: Fellow then Co-Principal Investigator; Big data study of lipids by density gradient                                ultracentrifugation. [http://clinicaltrials.gov/show/NCT01698489]

06/13 – present   Multi-Ethnic Study of Atherosclerosis                                                             

                            IRB00030361, Johns Hopkins Hospital

                            Role in Project: Co-Investigator, PI: Wendy Post; Prospective cohort study of cardiovascular disease.

 

09/13 – 03/15     mActive

                            IRB00086400, Johns Hopkins Hospital

                            Role in Project: Fellow then Co-Principal Investigator; A blinded, randomized mHealth trial of digital activity                              tracking and smart mobile phone text messaging. [http://clinicaltrials.gov/show/NCT01917812]

 

1/15 – present     Low-Density Lipoprotein Cholesterol Assessment Project                                           

                            IRB00057124, Johns Hopkins Hospital

                            Role in Project: Principal Investigator; A cardiology and laboratory medicine collaboration, involving Johns                              Hopkins Hospital and Mayo Clinic, to evaluate our novel LDL-C estimation algorithm. 

 

3/15 – 3/17          Long-term Extension of mActive Trial                                                            

                             IRB00054154, Johns Hopkins Hospital

                             Role in Project: Principal Investigator; Long-term follow-up of mActive trial participants.  

 

7/15 – 7/16         Validation of the Instant Blood Pressure Mobile Application                              

                             IRB00072333, Johns Hopkins Hospital

                          Role in Project: Principal Investigator; A study to determine the validity of the Instant Blood Pressure                               application (“IBP app”) in the measurement of blood pressure by comparing it to an automated                                sphygmomanometer. 

10/15 – present    mActive-Smoke                                                                                                          

                             IRB00077623, Johns Hopkins Hospital

                             Role in Project: Principal Investigator; A study of the real-time association between smoking addiction and                                              physical activity harnessing a novel precision medicine approach to guide tailored therapy.

 

12/15 – present    CASCADE-FH Registry

                             IRB00128273, Johns Hopkins Hospital

                             Role in Project: Principal Investigator; Multi-center registry of patients with familial hypercholesterolemia.

 

3/16 – present      Accuracy of Differential Diagnosis from Google Health Search and Impact on Clinical Encounters                                                  IRB00088552, Johns Hopkins Medical Institutions

                             Role in Project: Principal Investigator; Clinical trial to understand the accuracy of differential diagnoses                               generated via Google Health Search and the impact on clinical encounters. 

 

8/16 – present      Johns Hopkins MiCORE Study (Myocardial infarction, COmbined device, Recovery Enhancement)                              IRB00099938, Johns Hopkins Medical Institutions

                             Role in Project: Principal Investigator; Pilot study of the Corrie CareKit app, an iPhone and Apple Watch                               platform, in post-MI recovery.

 

3/17 – 1/18         Medication Adherence App Patient Feedback Survey                                         

                             IRB00122209, Johns Hopkins Medical Institutions

                             Role in Project: Principal Investigator; Pilot study of patients’ receptiveness to using a video-chat                                  interface application for social motivation and medication adherence, built through the Johns Hopkins                               Center for Bioengineering Innovation and Design (CBID) program.

6/17 – present      Pilot Study of Digital and Mobile Health Technology in Heart Failure Care and Patient Activation    

                             IRB00135748, Johns Hopkins Medical Institutions                                           

                             Role in Project: Principal Investigator; Pilot study as part of Stanford Med X Everyone Included competition                               evaluating digital monitoring and education in patient activation.

9/17 – present      Prevalence of Familial Chylomicronemia Syndrome          

                             IRB00150254, Johns Hopkins Medical Institutions                                           

                             Role in Project: Principal Investigator; the purpose of this project is to perform an electronic medical records     search to investigate the prevalence of Familial Chylomicronemia Syndrome (FCS) as part of a national     effort to better establish the prevalence of this rare and difficult to manage lipid disorder.

Inventions, Patents, Copyrights/Trademarks

10/20/13           Martin SS, Jones SR. Systems and methods for estimating low-density lipoprotein cholesterol from the                              standard lipid profile; Role: Co-Inventor. Status: Disclosed to Johns Hopkins Technology Ventures and                              patent application filed. Adopted in practice by Johns Hopkins Hospital and Quest Diagnostics.

3/27/17             Marvel FA, Lee MA, Martin SS. Corrie Health Digital Platform; Role: Co-Inventor. Status: Disclosed                              to Johns Hopkins Technology Ventures and trademark application filed.

 

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation Focus

I am faculty lead of the Johns Hopkins Corrie mobile health platform, a SI/QI initiative to reengineer the hospital discharge process. Currently we are using our platform to empower myocardial infarction patients in (1) skill-building for diet, exercise, and medication habits, (2) connecting with resources to help recovery, and (3) data analytics and biofeedback on steps, heart rate, and blood pressure with smart tools including an Apple Watch and Bluetooth blood pressure monitor. This patient self-management tool is provided early in admission to help patients improve their recovery and skills early.

 

System Innovation and Quality Improvement efforts within JHMI:

10/05 – present Core Faculty, Corrie Health Program, Faculty mentor for the interdisciplinary team consisting of software engineers, pre-medical students, medical students, and residents. Responsible for developing content for the platform and overseeing all aspects of the program.

System Innovation and Quality Improvement efforts outside JHMI:

8/07 – present Core Faculty, Corrie Health Program, Lead for program scaling to Reading Hospital (JHCRN), Medstar, University of Michigan, and Massachusetts General Hospital. Responsible for interfacing with teams at other hospitals and overseeing roll out.

 

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

2010-2011        Representative, Duke Internal Medicine Residency Council, Durham, NC

2012-present     Member, Evidence-Based Medicine Curriculum Workgroup for the Osler Medicine Residency Training Program, The Johns Hopkins Hospital, Baltimore, MD

2014                Leader, Fellows’ Distinguished Invited Speaker Series, The Johns Hopkins Hospital, Baltimore, MD

2015-present    Co-Chair, CVD/Aging mHealth Interest Group of Welch & Ciccarone Centers

2016-present      Member, Johns Hopkins University School of Medicine CME Advisory Board

 

Journal Peer-Review Activities

2011-present      Journal of the American College of Cardiology, Circulation, European Heart Journal, Clinical Cardiology, 

                          American Journal of Cardiology, American Heart Journal, Circulation Research, Annals of Internal 

                          Medicine (recognized as a top reviewer), Journal of the American Medical Association, New England 

                          Journal of Medicine, Lancet, JAMA Cardiology, American Journal of Medicine, Postgraduate Medicine, 

                          BMJ Open, Archives of Medical Research, JMIR, mHealth, Journal of Clinical Lipidology, Lipids in 

                          Health and Disease, Clinical Chemistry, Annals of Clinical Biochemistry, International Journal of 

                          Molecular Sciences, Biomarkers in Medicine, Diabetes, Obesity and Metabolism, Cardiovascular 

                          Diabetology, Journal of Cardiovascular Pharmacology and Therapeutics, Pharmacological Research, 

                          Chest, Atherosclerosis, Journal of Cardiovascular Computed Tomography, Echocardiography,                            PLosONE, Archives of Gerontology and Geriatrics, Annals of Epidemiology

 

Advisory Committees, Review Groups/Study Sections

2016-2017          Member, State Advisory Council on Heart Disease and Stroke Prevention, Maryland Department of                            Health and Mental Hygiene

2017-present      Member, State Advisory Council on Health and Wellness – Heart Committee, Maryland Department of                            Health and Mental Hygiene

2015-2016          Member, LDL: Address the Risk Think Tank work group, American College of Cardiology

2016-present      Member, Clinical and Scientific Advisory Board, Lipoprotein(a) Foundation

2017                   Grant Reviewer, EPIC Faculty Scholars Program

2017-present      DSMB Member, Molecular Transducers of Physical Activity in Humans (MoTrPAC), National Institute                      of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH) 2018                 Grant Reviewer, Mid-Atlantic NORC Pilot and Feasibility Grant, Mobile health technologies to achieve                       sustainable modification of obesity and cardiovascular risks to improve atrial fibrillation outcome

Editorial Board Appointments

2012-2015          Member, Fellow Editorial Board, Clinical Cardiology

2013-present      Member, Associate Editor, Acc.org Dyslipidemia Clinical Community

2013-2015          Member, Fellows Advisory Board, Cardiology Today

2015-present      Member, Editorial Board, Cardiology Today

2015-present      Associate Editor, BMJ Best Practice: Hypercholesterolaemia

2016-present      Associate Editor, Archives of Medical Science

2016-present      Associate Editor, Journal of Clinical Lipidology

2016-present      Contributing Editor, National Lipid Association Self-Assessment Program

2017-present      Consult Chief Editor, Cardiology, Medscape Consult

 

Professional Societies

2007-present      Member, American College of Physicians (ACP)

2008-present      Member, American Medical Association (AMA)

2008-present      Member, Sigma Xi International Honor Society in Scientific Research (SX)

2008-present      American Heart Association (AHA)

                         2008-present     Member (AHA)

                          2013-present Member, Greater Baltimore Young Hearts Board of Directors (AHA)

                          2014-present   Team Leader, Greater Baltimore Heart Walk (AHA)

                         2014-present    Abstract Grader, Annual Scientific Sessions (AHA)

                          2015-2018          Co-Chair, Maryland Young Hearts Board of Directors (AHA)

                          2015-present      Member, EPI Early Career Committee (AHA)

                          2015-present      Member, Science Clinical Education Lifelong Learning Committee (AHA)

                          2015-2017      Vice Chair, Maryland Advocacy Coordinating Committee (AHA)                

                         2017-present   Chair, Maryland Advocacy Coordinating Committee (AHA)

                        2017-present      Fellow (AHA)

                        2017-present     Member, Statistics Committee (AHA)

                       2018-present      Board Member, Mid-Atlantic Chapter (AHA)

2007-present      American College of Cardiology (ACC)

                         2007-present     Member (ACC)

                         2014-present    Abstract Grader, Annual Scientific Sessions (ACC)

                          2015-present   Fellow (ACC)

                        2018-present     Member, Innovation Council

2013-present      Member, The Thistle Society, Perelman School of Medicine at the University of Pennsylvania (TS)

2013-present      Member, Johns Hopkins Institute for Data-Intensive Engineering and Science (IDIES)

2013-present      Member, The FH Foundation (FHF)

2013-present      Member, The American Society of Preventive Cardiology (ASPC)

                         2018-present     Board Member (ASPC)

                          2018-present    Fellow (ASPC)

2018-present      Member, The National Lipid Association (NLA)

Conference Organizer

JHMI/Regional    None

 

National

2015-present      Planning Committee, American Heart Association Scientific Sessions

  • Planning Committee, LDL Address the Risk Think Tank, American Collee of Cardiology

2017-present      Planning Committee, Prevention Track for American College of Cardiology Scientific Sessions

  • Abstract Captain, Prevention Track for American College of Cardiology Scientific Sessions

International         None

Session Chair

JHMI/Regional    None

 

National

2016                   Session Co-Chair, Cutting Edge Methods in Big Data and Beyond, American Heart Association Scientific                             Sessions 2016, New Orleans, LA

  • Session Co-Chair, Late-Breaking Clinical Trials in Main Tent: Insights from New Therapeutic Trials for

                           Lipids, American Heart Association Scientific Sessions 2016, New Orleans, LA

  • Session Co-Chair, Great Debates in Preventive Cardiology, American College of Cardiology Scientific                     Sessions 2017, Washington, DC
  • Session Co-Chair, Precision Cardiovascular Disease Prevention: Practical Strategies to Personalize CVD

                        Prevention, American College of Cardiology Scientific Sessions 2018, Orlando, FL

International         

2018                            Session Co-Chair, Risk Stratification in Cardiovascular Diseases, Asian Pacific Society of Cardiology Congress, Taipei, Taiwan

Consultantships

2015                  Medical Advisory Board, Pressed Juicery

  • Scientific Advisory Board, Abbott Nutrition
  • Scientific Advisory Board, Quest Diagnostics

2016                  Consultant on PCSK9 inhibitors, Pew Research Center

2016                  Scientific Advisory Board, Sanofi-Regeneron

  • Medical Advisory Board on Connected Health, Under Armour
  • Scientific Advisory Board, Amgen

2017                  Scientific Advisory Board, Akcea Therapeutics

RECOGNITION   

Awards, Honors

Washington & Lee University, Lexington, VA

2001-2004         Intercollegiate Tennis Association Scholar-Athlete [2001; 2002; 2003; 2004]

2001-2004         Old Dominion Athletic Conference Scholar- Athlete [2001; 2002; 2003; 2004]

2003                  Vincent L. Bradford Merit Scholarship for academic promise

2003                  James L. Gavin Memorial Merit Scholarship for distinction in academics and leadership 2003                  Omicron Delta Kappa

  • Alpha Epsilon Delta
  • Phi Beta Kappa

2004                  Summa Cum Laude

2004                  Unsung General Award to student with greatest campus contributions 2004                  Order of Omega 

2004                  National Dean’s List

2004                  Who’s Who Among American Universities and Colleges

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

2008                  Research Day 2008 – 1st Prize in Clinical Scholarly Pursuit

2008                  ITMAT Research Paper Prize for Clinical Translational Research

  • Gertrude M. & Ezra M. Eisen Prize for outstanding performance in cardiology rotations and research Duke University Medical Center, Durham, NC
  • Robert M. Califf & Barton F. Haynes House Staff Research Award

2011                  Robert M. Califf & Barton F. Haynes House Staff Research Award

Johns Hopkins University School of Medicine, Baltimore, MD

  • Top Rated Reviewer for Annals of Internal Medicine
  • Johns Hopkins Division of Cardiology Research Retreat, Stanley L. Blumenthal, MD Cardiology Research

                         Award, 1st Prize for Clinical/Translational Research Oral Presentations

2012                  Up and Coming Future Stars of Cardiology, American College of Cardiology Foundation CardioSource 

                          World News

  • Outstanding Speaker Award for continuing education activity on Clinical Lipid and Lipoprotein

                          Diagnostics, American Association for Clinical Chemistry

  • Howard S. Silverman Research Award for Originality & Creativity in Medical Research

2013                  Best of AHA Specialty Conferences Award for top scoring abstract, AHA Quality of Care and Outcomes   

                          Scientific Sessions

2013                  Northwestern Cardiovascular Young Investigators’ Award – 2nd prize for Fellows’ Clinical Research

  • American College of Cardiology Mid-Atlantic Capital Young Investigators Award Competition Finalist
  • American College of Cardiology Legislative Conference Travel Award
  • Henry R. Kravis & Marie-Josée Cardiovascular Fellow

2015                  Steven N. Blair Award for Excellence in Physical Activity Research from the AHA’s Council on Lifestyle                                and Cardiometabolic Health

2015                  Anna Huffstutler Stiles Award from Johns Hopkins Bloomberg School of Public Health in recognition of                            outstanding achievements and innovative thesis research

2015                  Johns Hopkins Division of Cardiology Research Retreat, Blumenthal Cardiology Research Award

2015                  mHealth Scholar at National Institutes of Health 2015 Summer Institute on Mobile Technology

  • PJ Schafer Cardiovascular Research Award Recipient
  • Senior Author on Research Article of the Week, Department of Medicine, Johns Hopkins University

                          School of Medicine for article entitled, “Validation of the Instant Blood Pressure Smartphone App”

2016                  Faculty mentor for Dr. Plante, Recipient of W. Leigh Thompson Excellence in Clinical Research Fellow                           Award at the 2016 Hopkins DOM Research Retreat

2016                  Multi-Ethnic Study of Atherosclerosis Early Career Investigator Award

2016                  Faculty mentor for Dr. Quispe, Recipient of Johns Hopkins Division of Cardiology Research Retreat,                            Stanley L. Blumenthal, MD Cardiology Research Award

  • Faculty Mentor for Dr. Marvel, Corrie Health, Winner and Voted #1 Pitch by Audience at UberPITCH 2017 Cardiology Today Next Gen Innovators Award
  • Stanford Medicine X Global Research Challenge Finalist

2017                  Provider Behavioral Modification & Informatics category – Honorable Mention, 1st High Value Practice 

                          Academic Alliance National Research and Education Conference

2017                  Faculty mentor for Dr. Marvel, Corrie Project – 1st place for Clinical/Implementation Research Poster 

                          Presentation at the 8th Annual Johns Hopkins Cardiology Research Retreat

2017                  Faculty mentor on Corrie Project – 1st place for the Oral Research Presentation competition at the  

                         American College of Physicians Mulholland Mohler Residents Meeting, Baltimore, MD

  • Finalist, Corrie Health, ACC.18 Innovation Challenge, Orlando, FL
  • Selected as one of 125 current faculty members, fellows, postdocs, staff and students who personify                  Johns Hopkins Medicine’s mission to improve the health of the community and the world by setting the                     standard of excellence in medical education, research and clinical care, in celebration of the 125th Johns 

                        Hopkins Medicine anniversary.

2018                  Faculty mentor for Erin Spaulding, Corrie Project – 3rd place in Oral Competition at the 9th Annual  Johns Hopkins Cardiology Research Retreat

2018                  Faculty mentor on Corrie Project – 2nd place for the Oral Research Presentation competition at the  

                         American College of Physicians Mulholland Mohler Residents Meeting, Baltimore, MD

2018                Young Investigator Award for abstract analyzing FOURIER trial in collaboration with TIMI Study 

                      Group at Brigham and Women’s, National Lipid Association Scientific Sessions, Las Vegas, NV

Invited Talks

JHMI/Regional 

2014               Speaker, Critical Appraisal of the 2013 Risk Assessment and Lipid Rx Guidelines, Hopkins Cardiology 

                          Prevention Conference, Johns Hopkins Hospital, Baltimore, MD

2014               Speaker, Statins, Memory, and Mood: Where’s the Beef?, Hopkins Cardiology Prevention Conference, 

                          Johns Hopkins Hospital, Baltimore, MD

  • Speaker, Cardiovascular Controversies: “JNC8” and the Cholesterol Treatment Guideline, New Jersey

                          Academy of Family Physicians Scientific Assembly, Atlantic City, NJ

  • Speaker, Dyslipidemia Management Update: Where the ACC/AHA Guidelines are 2 Years Later and

                          How PCSK9 Inhibitors Change the Landscape, Endocrine Grand Rounds, Johns Hopkins Hospital, 

                          Baltimore, MD

  • Speaker, PCSK9 Inhibitors: A New Era in Lipid Management, Medicine Grand Rounds, Anne Arundel

                          Medical Center, Annapolis, MD 

  • Speaker, Using Big Data: The Very Large Database of Lipids, Current Topics Course, Department of

                          Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

2016      Speaker, mHealth: Opportunities and Growing Pains, CATALiST Seminar, The Johns Hopkins Institute                            for Clinical and Translational Research, Baltimore, MD

2016      Speaker, Mechanisms of Atherosclerosis: Central Role of Lipids, Cellular and Molecular Basis of Disease,                            Johns Hopkins University, Baltimore, MD

2016               Speaker, PCSK9 Inhibitors: A New Era in Lipid Management, Cardiologyf Grand Rounds, Hurd Hall, 

                       Johns Hopkins Hospital, Baltimore, MD

  • Speaker, Patient Interviews in Medication Management with Newer Cholesterol Therapies: Can We

                          Achieve Patient and Managed Care Homeostasis?, Academy of Managed Care Pharmacy Nexus 2016,                            National Harbor, MD

  • Speaker, PCSK9 Inhibitors: A New Era in Lipid Management, Medicine Grand Rounds, Johns Hopkins Bayview Medicine Center, Baltimore, MD

2017               Speaker, Precision and Innovation in Lipid Management, Seminar at Columbia University Medical 

                          Center, New York, NY

2017               Speaker, RICH LIFE Care Managers and Community Health Workers: Hyperlipidemia Training, Johns 

                          Hopkins Center to Eliminate Cardiovascular Health Disparities, Baltimore, MD

2017               Speaker, mHealth – Successes and Failures in Health Promotion, Reading Hospital Cardiovascular 

                          Update, Reading, PA

2017                  Speaker and Panelist, Patient Engagement Panel, Digital Health Day, Johns Hopkins University, Baltimore, MD

  • Speaker and Panelist, Mobilizing the Future of Clinical Research: A Perspective on App Development to

Improve Patient Outcomes, Johns Hopkins Clinical Research Network 3rd Annual Symposium, Johns Hopkins University School of Medicine, Baltimore, MD

  • Speaker, Dyslipidemia Management in 2018: Incorporating Precision and Innovation in Practice,

                      Endocrine Grand Rounds, Johns Hopkins Hospital, Baltimore, MD

2018               Speaker, PCSK9 Inhibitors: Crazy or Crazy Good?, Cardiology Grand Rounds, Hurd Hall, Johns 

                       Hopkins Hospital, Baltimore, MD

 

National

2014               Speaker, I am Forgetting the Title of My Talk: Are Statins to Blame?, American College of Cardiology 

                          Scientific Sessions

2014               Speaker, Statins Make Me Hurt, but I am Willing to Try. Do You Have Any Tricks? Approach to Statin 

                          Myalgia, American College of Cardiology Scientific Sessions

  • Speaker, Statin “Head Games”: Do Statins Worsen Cognition and Increase Cataracts and Hemorrhagic

                          Stroke? If So, So What?, American Heart Association Scientific Sessions

  • Speaker, An Objective Overview of PCSK9 Inhibitors, Best of ACC 2015 in Miami and Chicago

2015               Speaker, American Heart Association Presents: Working with the Individual with CVD: An 

                          Interdisciplinary Perspective, Society of Behavioral Medicine, San Antonio, TX

2015                Speaker, Pharmaceutical Pipeline (e.g. PCSK9s) and Innovations, AMCP Dyslipidemia Partnership 

                          Forum, Washington, DC

2015               Discussant, Do Statins Worsen Cognition and Increase Cataracts and Hemorrhagic Stroke?, American 

                          College of Cardiology ACCEL Audio Journal, with interview by Peter C. Block, MD, FACC

  • Speaker, Using Big Data: The Very Large Database of Lipids, National Lipid Association, Clinical Lipid

                          Update, San Diego, CA

  • Speaker, Blood Pressure Regulation: The Cardiologist’s View, Medicinal Chemistry, Washington and Lee

                          University, Lexington, VA

2016      Speaker, Building More Effective and “Friendlier” Systems of Care for Population Health, LDL: Address                            the Risk Think Tank, ACC Heart House, Washington, DC

  • Speaker, Challenges of Digital Health Clinical Trial Design and Execution in Session, Health Tech:

                          Mobilizing the Future of Clinical Research, American Heart Association Scientific Sessions 2016, New 

                          Orleans, LA

  • Speaker, A Managed Care Evaluation of the Dyslipidemia Management Advances, AMCP Webinar

2017                Speaker, Is Personalized Medicine Compatible with Public Health?, AHA EPI/Lifestyle Scientific 

                          Sessions, Portland, OR

2017                Speaker, mHealth – Friend or Bystander in Diabetes Management?, American Diabetes Association 77th 

                          Scientific Sessions, San Diego, CA

  • Speaker, Precision Medicine and Digital Health in Preventive Cardiology, Seminar at Houston Methodist Hospital, Houston, TX
  • Speaker, Technologies and the Future of Cardiovascular Practice, Case Studies in Clinical Practice: Patients as Consumers, American College of Cardiology Scientific Sessions

2018               Speaker, Prevention Section Closing Session, Top Three Presentations in Innovation/Digital

Platforms/mHealth/Precision Medicine Most Likely to Impact or Change Clinical Practice or Future Research Agendas, American College of Cardiology Scientific Sessions

2018                Speaker, Health Tech Panel: How Technology is Changing Cardiovascular Medicine, Inaugural

Cardiovascular Health Policy Summit, Washington, DC

International

  • Speaker, Towards Concordance on the Principle that Lipid Discordance Matters, McGill University Cardiology Grand Rounds, Montreal, Quebec, Canada
  • Speaker, New Drugs for the Management of LDL, 18th International Workshop on Co-Morbidities and

                          Adverse Drug Reactions in HIV, New York City, NY

  • Speaker, Guidelines for the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular

             Risk in Adults, American College of Cardiology and Russian Society of Cardiology, Joint Cardiovascular              Prevention Conference, St. Petersburg, Russia

2017               Speaker, Guidelines for the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular 

                      Risk in Adults, American College of Cardiology and Emirates Cardiac Society, Joint Cardiovascular 

                          Prevention Conference, Dubai, United Arab Emirates

2017               Speaker, Best Clinical Practices for Unstable Angina and NTE-ACS: A Case-Based Approach, Best of 

                          ACC Cardiovascular Symposium given four times in collaboration with local cardiologists in Chennai, 

                          India; Mumbai, India; Kathmandu, Nepal; and Dhaka, Bangladesh; talks tailored to each local culture

2017               Speaker, Latest Strategies in the Management of STEMI: A Case-Based Approach, Best of ACC 

                          Cardiovascular Symposium given four times in collaboration with local cardiologists in Chennai, India; 

                          Mumbai, India; Kathmandu, Nepal; and Dhaka, Bangladesh; talks tailored to each local culture

2017               Visiting Professorship, Guangdong General Hospital, Guangzhou, China, “Precision Medicine and

Digital Health: How Accurate and Actionable Information re Shaping the Future of Preventive Cardiology”

  • Speaker, Risk Factor Burden and Risk Management of Cardiovascular Disease, American College of

Cardiology and Saudi Heart Association, Joint Cardiovascular Prevention Conference, King Abdullah Economic City, Saudi Arabia

  • Speaker, Leadership Address, Emerging Leaders 2018 Program Dinner, Asian Pacific Society of                    Cardiology Congress, Taipei, Taiwan

2018                   Speaker, Global Cardiovascular Risk Assessment: Framingham Risk Score, Reynolds Risk Score, 

                        SCORE, and Pooled Cohort Equations, Asian Pacific Society of Cardiology Congress, Taipei, Taiwan